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Introduction
In February 1994, the Pediatric AIDS Clinical Trials Group
(PACTG) Protocol 076 demonstrated that a three-part
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Summary
These recommendations update the February 4, 2002, guidelines developed by the Public Health Service for the use of zidovudine
(ZDV) to reduce the risk for perinatal human immunodeficiency virus type 1 (HIV-1) transmission. This report provides health-
care providers with information for discussion with HIV-1–infected pregnant women to enable such women to make an informed
decision regarding the use of antiretroviral drugs during pregnancy and use of elective cesarean delivery to reduce perinatal HIV-1
transmission. Various circumstances that commonly occur in clinical practice are presented, and the factors influencing treatment
considerations are highlighted in this report. The Perinatal HIV Guidelines Working Group recognizes that strategies to prevent
perinatal transmission and concepts related to management of HIV disease in pregnant women are rapidly evolving and will
continually review new data and provide regular updates to the guidelines. The most recent information is available from the
HIV/AIDS Treatment Information Service (available at http://www.hivatis.org).
In February 1994, the results of Pediatric AIDS Clinical Trials Group (PACTG) Protocol 076 documented that ZDV chemo-
prophylaxis could reduce perinatal HIV-1 transmission by nearly 70%. Epidemiologic data have since confirmed the efficacy of
ZDV for reduction of perinatal transmission and have extended this efficacy to children of women with advanced disease, low
CD4+ T-lymphocyte counts, and prior ZDV therapy. Additionally, substantial advances have been made in the understanding of
the pathogenesis of HIV-1 infection and in the treatment and monitoring of persons with HIV-1 disease. These advances have
resulted in changes in standard antiretroviral therapy for HIV-1–infected adults. More aggressive combination drug regimens that
maximally suppress viral replication are now recommended. Although considerations associated with pregnancy may affect deci-
sions regarding timing and choice of therapy, pregnancy is not a reason to defer standard therapy. Use of antiretroviral drugs in
pregnancy requires unique considerations, including the possible need to alter dosage as a result of physiologic changes associated
with pregnancy, the potential for adverse short- or long-term effects on the fetus and newborn, and the effectiveness of the drugs in
reducing the risk for perinatal transmission. Data to address many of these considerations are not yet available. Therefore, offering
antiretroviral therapy to HIV-1–infected women during pregnancy, whether primarily for HIV-1 infection, for reduction of
perinatal transmission, or for both purposes, should be accompanied by a discussion of the known and unknown short- and long-
term benefits and risks of such therapy to infected women and their infants. Standard antiretroviral therapy should be discussed
with and offered to HIV-1–infected pregnant women. Additionally, to prevent perinatal transmission, ZDV chemoprophylaxis
should be incorporated into the antiretroviral regimen.
regimen of zidovudine (ZDV) could reduce the risk for mother-
to-child human immunodeficiency virus type 1 (HIV-1)
transmission by nearly 70% (1). The regimen includes oral
ZDV initiated at 14–34 weeks’ gestation and continued
throughout pregnancy, followed by intravenous ZDV during
labor and oral administration of ZDV to the infant for 6 weeks
after delivery (Table 1). In August 1994, a U.S. Public Health
Service (USPHS) task force issued recommendations for the
use of ZDV for reduction of perinatal HIV-1 transmission
*Information included in these guidelines may not represent approval by the Food and Drug Administration (FDA) or approved labeling for the particular product
or indications in question. Specifically, the terms “safe” and “effective” may not be synonymous with the FDA-defined legal standards for product approval.
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(2), and in July 1995, USPHS issued recommendations for
universal prenatal HIV-1 counseling and HIV-1 testing with
consent for all pregnant women in the United States (3). Since
the publication of the results of PACTG 076, epidemiologic
studies in the United States and France have demonstrated
dramatic decreases in perinatal transmission with incorpora-
tion of the PACTG 076 ZDV regimen into general clinical
practice (4–9).
Since 1994, advances have been made in the understanding
of the pathogenesis of HIV-1 infection and in the treatment
and monitoring of HIV-1 disease. The rapidity and magni-
tude of viral turnover during all stages of HIV-1 infection are
greater than previously recognized; plasma virions are estimated
to have a mean half-life of only 6 hours (10). Thus, current
therapeutic interventions focus on early initiation of aggres-
sive combination antiretroviral regimens to maximally sup-
press viral replication, preserve immune function, and reduce
the development of resistance (11). New, potent antiretroviral
drugs that inhibit the protease enzyme of HIV-1 are now avail-
able. When a protease inhibitor is used in combination with
nucleoside analog reverse transcriptase inhibitors, plasma HIV-1
RNA levels can be reduced for prolonged periods to levels
that are undetectable by current assays. Improved clinical out-
come and survival have been observed among adults receiving
such regimens (12,13). Additionally, viral load can now be
more directly quantified through assays that measure HIV-1
RNA copy number; these assays have provided powerful new
tools to assess disease stage, risk for progression, and the
effects of therapy. These advances have led to substantial




Antepartum Oral administration of 100 mg ZDV five times daily,*
initiated at 14–34 weeks’ gestation and continued
throughout the pregnancy.
Intrapartum During labor, intravenous administration of ZDV in a
1-hour initial dose of 2 mg/kg body weight, followed
by a continuous infusion of 1 mg/kg body weight
per hour until delivery.
Postpartum Oral administration of ZDV to the newborn (ZDV
syrup at 2 mg/kg body weight/dose every 6 hours)
for the first 6 weeks of life, beginning at 8–12 hours
after birth.†
* Oral ZDV, administered as 200 mg three times daily or 300 mg twice
daily, is used in general clinical practice and is an acceptable alternative
regimen to 100 mg orally five times daily.
†
Intravenous dosage for infants who cannot tolerate oral intake is 1.5 mg/
kg body weight intravenously every 6 hours.
changes in the standard of treatment and monitoring for HIV-
1–infected adults in the United States (14).
Advances also have been made in the understanding of the
pathogenesis of perinatal HIV-1 transmission. Most perinatal
transmission likely occurs close to the time of or during child-
birth (15). Additional data that demonstrate the short-term
safety of the ZDV regimen are now available as a result of
follow-up of infants and women enrolled in PACTG 076;
however, data from studies of animals concerning the poten-
tial for transplacental carcinogenicity of ZDV affirm the
need for long-term follow-up of children with antiretroviral
exposure in utero (16).
These advances have implications for maternal and fetal
health. Health-care providers considering the use of
antiretroviral agents for HIV-1–infected women during preg-
nancy must take into account two separate but related issues:
1) antiretroviral treatment of maternal HIV-1 infection, and
2) antiretroviral chemoprophylaxis to reduce the risk for peri-
natal HIV-1 transmission. The benefits of antiretroviral therapy
for a pregnant woman must be weighed against the risk of
adverse events to the woman, fetus, and newborn. Although
ZDV chemoprophylaxis alone has substantially reduced the
risk for perinatal transmission, antiretroviral monotherapy is
now considered suboptimal for treatment of HIV-1 infection,
and combination drug regimens are considered the standard
of care for therapy (14).
This report reviews the special considerations regarding use
of antiretroviral drugs for pregnant women, updates the
results of PACTG 076 and related clinical trials and epide-
miologic studies, discusses use of HIV-1 RNA and
antiretroviral drug resistance assays during pregnancy, provides
updated recommendations on antiretroviral chemoprophylaxis
for reducing perinatal transmission, and provides recommen-
dations related to use of elective cesarean delivery as an inter-
vention to reduce perinatal transmission.
These recommendations have been developed for use in the
United States. Although perinatal HIV-1 transmission occurs
worldwide, alternative strategies may be appropriate in other
countries. Policies and practices in other countries
regarding the use of antiretroviral drugs for reduction of peri-
natal HIV-1 transmission may differ from the recommenda-
tions in this report and will depend on local considerations,
including availability and cost of ZDV, access by pregnant
women to facilities for safe intravenous infusions during
labor, and alternative interventions being evaluated in that
area.
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Background
Considerations Regarding Use of
Antiretroviral Drugs by HIV-1–infected
Pregnant Women and Their Infants
Treatment recommendations for pregnant women infected
with HIV-1 have been based on the belief that therapies of
known benefit to women should not be withheld during preg-
nancy unless there are known adverse effects on the mother,
fetus, or infant and unless these adverse effects outweigh the
benefit to the woman (17). Combination antiretroviral therapy,
usually consisting of two nucleoside analog reverse transcriptase
inhibitors and a protease inhibitor, is the recommended stan-
dard treatment for HIV-1–infected adults who are not preg-
nant (14). Pregnancy should not preclude the use of optimal
therapeutic regimens. However, recommendations regarding
the choice of antiretroviral drugs for treatment of infected
pregnant women are subject to unique considerations. These
include possible changes in dosing requirements resulting from
physiologic changes associated with pregnancy, potential
effects of antiretroviral drugs on the pregnant woman, and
the potential short- and long-term effects of the antiretroviral
drug on the fetus and newborn, which may not be known for
certain antiretroviral drugs.
The decision to use any antiretroviral drug during pregnancy
should be made by the woman after discussing with her health-
care provider the known and unknown benefits and risks to
her and her fetus.
Physiologic changes that occur during pregnancy may
affect the kinetics of drug absorption, distribution, biotrans-
formation, and elimination, thereby also affecting requirements
for drug dosing and potentially altering the susceptibility of
the pregnant woman to drug toxicity. During pregnancy,
gastrointestinal transit time becomes prolonged; body water
and fat increase throughout gestation and are accompanied
by increases in cardiac output, ventilation, and liver and renal
blood flow; plasma protein concentrations decrease; renal
sodium reabsorption increases; and changes occur in meta-
bolic enzyme pathways in the liver. Placental transport of drugs,
compartmentalization of drugs in the embryo/fetus and pla-
centa, biotransformation of drugs by the fetus and placenta,
and elimination of drugs by the fetus also can affect drug phar-
macokinetics in the pregnant woman. Additional consider-
ations regarding drug use in pregnancy are the effects of the
drug on the fetus and newborn, including the potential for
teratogenicity, mutagenicity, or carcinogenicity, and the phar-
macokinetics and toxicity of transplacentally transferred drugs.
The potential harm to the fetus from maternal ingestion of
a specific drug depends not only on the drug itself, but on the
dose ingested, the gestational age of the fetus at exposure, the
duration of exposure, the interaction with other agents to
which the fetus is exposed, and, to an unknown extent, the
genetic makeup of the mother and fetus.
Information regarding the safety of drugs in pregnancy is
derived from animal toxicity data, anecdotal experience,
registry data, and clinical trials. Data are limited for
antiretroviral drugs, particularly when used in combination
therapy. Drug choice should be individualized and must be
based on discussion with the woman and available data from
preclinical and clinical testing of the individual drugs.
Preclinical data include results of in vitro and animal
in vivo screening tests for carcinogenicity, clastogenicity/
mutagenicity, and reproductive and teratogenic effects. How-
ever, the predictive value of such tests for adverse effects in
humans is unknown. For example, of approximately 1,200
known animal teratogens, only about 30 are known to be ter-
atogenic in humans (18). In addition to antiretroviral agents,
certain drugs commonly used to treat HIV-1–related illnesses
demonstrate positive findings on one or more of these screen-
ing tests. For example, acyclovir is positive in some in vitro
carcinogenicity and clastogenicity assays and is associated with
fetal abnormalities in rats; however, data collected on the
basis of human experience from the Acyclovir in Pregnancy
Registry have indicated no increased risk for birth defects in
infants with in utero exposure to acyclovir (19). Limited data
exist regarding placental passage and long-term animal carci-




Data are conflicting as to whether receipt of combination
antiretroviral therapy during pregnancy is associated with
adverse pregnancy outcomes such as preterm delivery. A ret-
rospective Swiss report evaluated the pregnancy outcome of
37 HIV-1–infected pregnant women treated with combina-
tion therapy; all received two reverse transcriptase inhibitors
and 16 received one or two protease inhibitors (21). Almost
80% of women experienced one or more typical adverse
effects of the drugs, such as anemia, nausea/vomiting,
aminotransferase elevation, or hyperglycemia. A possible
association of combination antiretroviral therapy with preterm
births was noted; 10 of 30 babies were born prematurely. The
preterm birth rate did not differ between women receiving










studies Animal teratogen studies
TABLE 2. Preclinical and clinical data relevant to the use of antiretroviral agents in pregnancy

































































































Positive (rodent, near lethal dose)
Positive (rodent, hydrocephalus at high
dose)
Negative
Negative (but sternal bone calcium
decreases in rodents)
Negative
Positive (rodent, anasarca and skeletal mal-
formations at 1000 mg/kg (35x human exposure)
during organogenesis; not seen in rabbits)
Negative (osteomalacia when given to
juvenile animals at high doses)
Negative
Positive (rodent, ventricular septal defect)
Positive (cynomologus monkey, anencephaly,
anophthalmia, microophthalmia)
Negative (but extra ribs in rodents)
Negative (but cryptorchidism in rodents)
Negative
Negative
Negative (but deficient ossification and
thymic elongation in rats and rabbits)
Negative (but delayed skeletal ossification
and increase in skeletal variations in rats at
maternally toxic doses)
Non-nucleoside reverse transcriptase inhibitors
Protease inhibitors
* FDA pregnancy categories:
A Adequate and well-controlled studies of pregnant women fail to demonstrate a risk to the fetus during the first trimester of pregnancy (and there is no
evidence of risk during later trimesters).
B Animal reproduction studies fail to demonstrate a risk to the fetus, and adequate and well-controlled studies of pregnant women have not been conducted.
C Safety in human pregnancy has not been determined, animal studies are either positive for fetal risk or have not been conducted, and the drug should
not be used unless the potential benefit outweighs the potential risk to the fetus.
D Positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experiences, but the potential benefits from the
use of the drug in pregnant women may be acceptable despite its potential risks.
X Studies with animals or reports of adverse reactions have indicated that the risk associated with the use of the drug for pregnant women clearly
outweighs any possible benefit.
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combination therapy with or without protease inhibitors. The
contribution of maternal HIV-1 disease stage and other
covariates that might be associated with a risk for prematurity
was not assessed.
The European Collaborative Study and the Swiss Mother +
Child HIV-1 Cohort Study investigated the effects of combi-
nation retroviral therapy in a population of 3,920 mother–
child pairs. Adjusting for CD4+ T-lymphocyte count (CD4+
count) and intravenous drug use, they found a 2.6-fold (95%
confidence interval [CI] = 1.4–4.8) increased odds of preterm
delivery for infants exposed to combination therapy with or
without protease inhibitors compared with no treatment;
women receiving combination therapy that had been initi-
ated before their pregnancy were twice as likely to deliver
prematurely as those starting therapy during the third trimes-
ter (22). However, combination therapy was received by only
323 (8%) women studied. Exposure to monotherapy was not
associated with prematurity.
In contrast, in an observational study of pregnant women
with HIV-1 infection in the United States (PACTG 367) in
which 1,150 (78%) of 1,472 women received combination
therapy, no association was found between receipt of combi-
nation therapy and preterm birth (23). The highest rate of
preterm delivery was among women who had not received
any antiretroviral therapy, which is consistent with several other
reports demonstrating elevated preterm birth rates among
untreated women with HIV-1 infection (24–26). In a French
open-label study of 445 HIV-1–infected women receiving
ZDV who had lamivudine (3TC) added to their therapy at
32 weeks’ gestation, the rate of preterm delivery was 6%, similar
to the 9% rate in a historical control group of women receiv-
ing only ZDV (27). Additionally, in a large meta-analysis of
seven clinical studies that included 2,123 HIV-infected preg-
nant women who delivered infants during 1990–1998 and
had received antenatal antiretroviral therapy and 1,143 women
who did not receive antenatal antiretroviral therapy, use of
multiple antiretroviral drugs as compared with no treatment
or treatment with one drug was not associated with increased
rates  of preterm labor, low birth weight, low Apgar scores, or
stillbirth (28).
Until more information is known, HIV-1–infected preg-
nant women who are receiving combination therapy for their
HIV-1 infection should continue their provider-recommended
regimen. They should receive careful, regular monitoring for
pregnancy complications and for potential toxicities.
Protease Inhibitor Therapy
and Hyperglycemia
Hyperglycemia, new-onset diabetes mellitus, exacerbation
of existing diabetes mellitus, and diabetic ketoacidosis have
been reported with receipt of protease inhibitor antiretroviral
drugs by HIV-1–infected patients (29–32). In addition, preg-
nancy is itself a risk factor for hyperglycemia; it is unknown
if the use of protease inhibitors will increase the risk for
pregnancy-associated hyperglycemia. Clinicians caring for
HIV-1–infected pregnant women who are receiving protease
inhibitor therapy should be aware of the risk of this complica-
tion and closely monitor glucose levels. Symptoms of hyper-
glycemia should be discussed with pregnant women who are
receiving protease inhibitors.
Mitochondrial Toxicity and Nucleoside
Analog Drugs
Nucleoside analog drugs are known to induce mitochon-
drial dysfunction because the drugs have varying affinity for
mitochondrial gamma DNA polymerase. This affinity can
interfere with mitochondrial replication, resulting in mito-
chondrial DNA depletion and dysfunction (33). The relative
potency of the nucleosides in inhibiting mitochondrial gamma
DNA polymerase in vitro is highest for zalcitabine (ddC), fol-
lowed by didanosine (ddI), stavudine (d4T), 3TC, ZDV and
abacavir (ABC) (34). Toxicity related to mitochondrial dys-
function has been reported to occur in infected patients
receiving long-term treatment with nucleoside analogs and gen-
erally has resolved with discontinuation of the drug or drugs;
a possible genetic susceptibility to these toxicities has been
suggested (33). These toxicities may be of particular concern
for pregnant women and infants with in utero exposure to
nucleoside analog drugs.
During Pregnancy
Clinical disorders linked to mitochondrial toxicity include
neuropathy, myopathy, cardiomyopathy, pancreatitis, hepatic
steatosis, and lactic acidosis. Among these disorders, symp-
tomatic lactic acidosis and hepatic steatosis may have a female
preponderance (35). These syndromes have similarities to rare
but life-threatening syndromes that occur during pregnancy,
most often during the third trimester: acute fatty liver, and
the combination of hemolysis, elevated liver enzymes and low
platelets (the HELLP syndrome). Several investigators have
6 MMWR November 22, 2002
correlated these pregnancy-related disorders with a recessively
inherited mitochondrial abnormality in the fetus/infant that
results in an inability to oxidize fatty acids (36–38). Since the
mother would be a heterozygotic carrier of the abnormal gene,
the risk for liver toxicity might be increased during pregnancy
because the mother would be unable to properly oxidize both
maternal and accumulating fetal fatty acids (39). Addition-
ally, animal studies have demonstrated that in late gestation,
pregnant mice have significant reductions (25%–50%) in
mitochondrial fatty acid oxidation and that exogeneously
administered estradiol and progesterone can reproduce these
effects (40,41); whether this can be translated to humans is
unknown. However, these data suggest that a disorder of
mitochondrial fatty acid oxidation in the mother or her fetus
during late pregnancy may play a role in the development of
acute fatty liver of pregnancy and HELLP syndrome and pos-
sibly contribute to susceptibility to antiretroviral-associated
mitochondrial toxicity.
Lactic acidosis with microvacuolar hepatic steatosis is a tox-
icity related to nucleoside analog drugs that is thought to be
related to mitochondrial toxicity; it has been reported to
occur in infected persons treated with nucleoside analog drugs
for long periods (>6 months). Initially, most cases were asso-
ciated with ZDV, but later other nucleoside analog drugs,
particularly d4T, have been associated with the syndrome. In
a report from the FDA Spontaneous Adverse Event Program
of 106 patients with this syndrome (60 receiving combina-
tion and 46 receiving single nucleoside analog therapy), typi-
cal initial symptoms included 1 to 6 weeks of nausea, vomiting,
abdominal pain, dyspnea, and weakness (35). Metabolic aci-
dosis with elevated serum lactate and elevated hepatic enzymes
was common. Patients described in that report were predomi-
nantly female and overweight. The incidence of this syndrome
may be increasing, possibly as a result of increased use of com-
bination nucleoside analog therapy or increased recognition
of the syndrome. In a cohort of infected patients receiving
nucleoside analog therapy followed at Johns Hopkins Univer-
sity during 1989–1994, the incidence of the hepatic steatosis
syndrome was 0.13% per year (42). However, in a report from
a cohort of 964 HIV-1–infected persons followed in France
for 2 years during 1997–1999, the incidence of symptomatic
hyperlactatemia was 0.8% per year for all patients and 1.2%
for patients receiving a regimen including d4T (43).
The frequency of this syndrome in pregnant HIV-1–infected
women receiving nucleoside analog treatment is unknown. In
1999, Italian researchers reported a case of severe lactic acido-
sis in an infected pregnant woman who was receiving d4T-
3TC at the time of conception and throughout pregnancy
and who experienced symptoms and fetal death at 38 weeks’
gestation (44). Bristol-Myers Squibb has reported three
maternal deaths due to lactic acidosis, two with and one with-
out accompanying pancreatitis, among women who were
either pregnant or postpartum and whose antepartum therapy
during pregnancy included d4T and ddI in combination with
other antiretroviral agents (either a protease inhibitor or
nevirapine) (45). All women were receiving treatment with
these agents at the time of conception and continued for the
duration of pregnancy; all presented late in gestation with
symptomatic disease that progressed to death in the immedi-
ate postpartum period. Two cases were also associated with
fetal death.
It is unclear if pregnancy augments the incidence of the
lactic acidosis/hepatic steatosis syndrome that has been
reported for nonpregnant persons receiving nucleoside
analog treatment. However, because pregnancy itself can
mimic some of the early symptoms of the lactic acidosis/
hepatic steatosis syndrome or be associated with other disor-
ders of liver metabolism, these cases emphasize the need for
physicians caring for HIV-1–infected pregnant women receiv-
ing nucleoside analog drugs to be alert for early signs of this
syndrome. Pregnant women receiving nucleoside analog drugs
should have hepatic enzymes and electrolytes assessed more
frequently during the last trimester of pregnancy, and any new
symptoms should be evaluated thoroughly. Additionally,
because of the reports of several cases of maternal mortality
secondary to lactic acidosis with prolonged use of the combi-
nation of d4T and ddI by HIV-1–infected pregnant women,
clinicians should prescribe this antiretroviral combination
during pregnancy with caution and generally only when other
nucleoside analog drug combinations have failed or have caused
unacceptable toxicity or side effects.
In Utero Exposure
A study conducted in France reported that in a cohort of
1,754 uninfected infants born to HIV-1–infected women who
received antiretroviral drugs during pregnancy, eight infants
with in utero or neonatal exposure to either ZDV-3TC (four
infants) or ZDV alone (four infants) developed indications of
mitochondrial dysfunction after the first few months of life
(46). Two of these infants (both of whom had been exposed
to ZDV-3TC) contracted severe neurologic disease and died,
three had mild to moderate symptoms, and three had no symp-
toms but had transient laboratory abnormalities. An associa-
tion between these findings and in utero exposure to
antiretroviral drugs has not been definitively established.
In infants followed through age 18 months in PACTG 076,
the occurrence of neurologic events was rare; seizures occurred
in one child exposed to ZDV and two exposed to placebo,
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and one child in each group had reported spasticity. Mortality
at 18 months was 1.4% among infants given ZDV compared
with 3.5% among those given placebo (47). The Perinatal
Safety Review Working Group performed a retrospective
review of deaths occurring among children born to HIV-1–
infected women and followed during 1986–1999 in five large
prospective U.S. perinatal cohorts. No deaths similar to those
reported from France or with clinical findings attributable to
mitochondrial dysfunction were identified in a database of
>16,000 uninfected children born to HIV-1–infected women
with and without antiretroviral drug exposure (48). However,
most of the infants with antiretroviral exposure had been
exposed to ZDV alone and only a relatively small proportion
(approximately 6%) had been exposed to ZDV-3TC. In an
African perinatal trial (PETRA) that compared three regimens
of ZDV-3TC (during pregnancy starting at 36 weeks’ gesta-
tion, during labor, and through 1 week postpartum; during
labor and postpartum; and during labor only) with placebo
for prevention of transmission, data have been reviewed relat-
ing to neurologic adverse events among 1,798 children who
participated. No increased risk of neurologic events was
observed among children treated with ZDV-3TC compared
with placebo, regardless of the intensity of treatment (49).
Finally, in a study of 382 uninfected infants born to HIV-1–
infected women, echocardiograms were prospectively per-
formed every 4 to 6 months during the first 5 years of life; 9%
of infants had been exposed to ZDV prenatally (50). No
significant differences in ventricular function were observed
between infants exposed and not exposed to ZDV.
Even if the association of mitochondrial dysfunction and in
utero antiretroviral exposures is demonstrated, the develop-
ment of severe or fatal mitochondrial disease in these infants
appears to be extremely rare and should be compared against
the clear benefit of ZDV in reducing transmission of a fatal
infection by nearly 70% (51). These results emphasize the
importance of the existing Public Health Service recommen-
dation for long-term follow-up for any child with in utero
exposure to antiretroviral drugs.
Antiretroviral Pregnancy Registry
Health-care providers who are treating HIV-1–infected preg-
nant women and their newborns are strongly advised to
report instances of prenatal exposure to antiretroviral drugs
(either alone or in combination) to the Antiretroviral Preg-
nancy Registry. This registry is an epidemiologic project to
collect observational, nonexperimental data regarding
antiretroviral exposure during pregnancy for the purpose of
assessing the potential teratogenicity of these drugs. Registry
data will be used to supplement animal toxicology studies and
assist clinicians in weighing the potential risks and benefits of
treatment for individual patients. The Antiretroviral Pregnancy
Registry is a collaborative project of pharmaceutical manufac-
turers with an advisory committee of obstetric and pediatric
practitioners. The registry does not use patient names, and
registry staff obtain birth outcome follow-up information from








Update on PACTG 076 Results
and Other Studies Relevant to ZDV
Chemoprophylaxis for Perinatal
HIV-1 Transmission
In 1996, final results were reported for all 419 infants
enrolled in PACTG 076. The results concur with those ini-
tially reported in 1994; the Kaplan-Meier estimated HIV-1
transmission rate for infants who received placebo was 22.6%,
compared with 7.6% for those who received ZDV, a 66%
reduction in risk for transmission (52).
The mechanism by which ZDV reduced transmission in
PACTG 076 participants has not been fully defined. The
effect of ZDV on maternal HIV-1 RNA does not fully
account for the observed efficacy of ZDV in reducing trans-
mission. Preexposure prophylaxis of the fetus or infant may
offer substantial protection. If so, transplacental passage of
antiretroviral drugs would be crucial for prevention of trans-
mission. Additionally, in placental perfusion studies, ZDV has
been metabolized into the active triphosphate within the pla-
centa (53,54), which could provide additional protection
against in utero transmission. This phenomenon may be
unique to ZDV because metabolism to the active triphosphate
form within the placenta has not been observed in the other
nucleoside analogs that have been evaluated (i.e., ddI and ddC)
(55,56).
In PACTG 076, similar rates of congenital abnormalities
occurred among infants with and without in utero ZDV
exposure. Data from the Antiretroviral Pregnancy Registry also
have demonstrated no increased risk for congenital abnormali-
ties among infants born to women who receive ZDV
antenatally compared with the general population (57). Among
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uninfected infants from PACTG 076 followed from birth to
a median age of 4.2 years (range 3.2–5.6 years), no differences
were noted in growth, neurodevelopment, or immunologic
status between infants born to mothers who received ZDV
compared with those born to mothers who received placebo
(58). No malignancies have been observed in short-term (i.e.,
up to age 6 years) follow-up of >727 infants from PACTG
076 or from a prospective cohort study involving infants with
in utero ZDV exposure (59). However, follow-up is too lim-
ited to provide a definitive assessment of carcinogenic risk
with human exposure. Long-term monitoring continues to
be recommended for all infants who have received in utero
ZDV exposure or in utero exposure to any of the antiretroviral
drugs.
The efficacy of ZDV chemoprophylaxis for reducing HIV-1
transmission among populations of infected women with char-
acteristics unlike those of the PACTG 076 population has
been evaluated in another perinatal protocol (PACTG 185)
and in prospective cohort studies. PACTG 185 enrolled preg-
nant women with advanced HIV-1 disease and low CD4+
counts who were receiving antiretroviral therapy; 24% had
received ZDV before the current pregnancy (60). All women
and infants received the three-part ZDV regimen combined
with either infusions of hyperimmune HIV-1 immunoglobu-
lin (HIVIG) containing high levels of antibodies to HIV-1 or
standard intravenous immunoglobulin (IVIG) without HIV-1
antibodies. Because advanced maternal HIV-1 disease has been
associated with increased risk for perinatal transmission, the
transmission rate in the control group was hypothesized to be
11%–15% despite the administration of ZDV. At the first
interim analysis, the transmission rate for the combined group
was only 4.8% and did not substantially differ by whether the
women received HIVIG or IVIG or by duration of ZDV use
(60). The results of this trial confirm the efficacy of ZDV
observed in PACTG 076 and extend this efficacy to women
with advanced disease, low CD4+ count, and prior ZDV
therapy. Rates of perinatal transmission have been documented
to be as low as 3%–4% among women with HIV-1 infection
who receive all three components of the ZDV regimen,
including women with advanced HIV-1 disease (6,60).
At least two studies suggest that antenatal use of combina-
tion antiretroviral regimens might further reduce transmis-
sion. In an open-label, nonrandomized study of 445 women
with HIV-1 infection in France, 3TC was added at 32 weeks’
gestation to standard ZDV prophylaxis; 3TC was also given
to the infant for 6 weeks in addition to ZDV (27). The trans-
mission rate in the ZDV-3TC group was 1.6% (95% CI =
0.7%–3.3%); in comparison, the transmission rate in a his-
torical control group of women receiving only ZDV was 6.8%
(95% CI = 5.1%–8.7%). In a longitudinal epidemiologic study
conducted in the United States since 1990, transmission was
observed in 20% of women with HIV-1 infection who
received no antiretroviral treatment during pregnancy, 10.4%
who received ZDV alone, 3.8% who received combination
therapy without protease inhibitors, and 1.2% who received
combination therapy with protease inhibitors (61).
International Antiretroviral Prophylaxis
Clinical Trials
In a trial evaluating short-course antenatal/intrapartum ZDV
prophylaxis and perinatal transmission among non-
breastfeeding women in Thailand, administration of ZDV 300
mg twice daily for 4 weeks antenatally and 300 mg every 3
hours orally during labor was shown to reduce perinatal trans-
mission by approximately 50% compared with placebo (62).
The transmission rate was 19% in the placebo group versus
9% in the ZDV group. A second, four-arm factorial design
trial in Thailand compared administration of ZDV antenatally
starting at 28 or 36 weeks’ gestation, orally intrapartum, and
to the neonate for 3 days or 6 weeks. At an interim analysis,
the transmission rate in the arm receiving ZDV antenatally
starting at 36 weeks and postnatally for 3 days to the infant
was 10%, which was significantly higher than for the long–
long arm (antenatal starting at 28 weeks and infant adminis-
tration for 6 weeks) (63). The transmission rate in the
short–short arm of this study was similar to the 9% observed
with short antenatal/intrapartum ZDV in the first Thai study.
The rate of in utero transmission was higher among women
in the short antenatal arms compared with those receiving
longer antenatal therapy, suggesting that longer treatment of
the infant cannot substitute for longer treatment of the mother.
A third trial in Africa (PETRA trial) among breastfeeding
HIV-1–infected women has shown that a combination regi-
men of ZDV and 3TC administered starting at 36 weeks’ ges-
tation, orally intrapartum, and for 1 week postpartum to the
woman and infant reduced transmission at age 6 weeks by
approximately 50% compared with placebo (64). The trans-
mission rate at age 6 weeks was 15% in the placebo group
versus 6% with the three-part ZDV-3TC regimen. This effi-
cacy is similar to the efficacy observed in the Thailand study
of antepartum/intrapartum short-course ZDV in non-
breastfeeding women (62).
Investigators have identified two possible intrapartum/
postpartum regimens (either ZDV-3TC or nevirapine) that
could provide an effective intrapartum/postpartum interven-
tion for women for whom the diagnosis of HIV-1 is not made
until near to or during labor. The PETRA African ZDV-3TC
trial among breastfeeding HIV-1–infected women also
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demonstrated that an intrapartum/postpartum regimen,
started during labor and continued for 1 week postpartum in
the woman and infant, reduced transmission at age 6 weeks
from 15% in the placebo group to 9% in the group receiving
the two-part ZDV-3TC regimen, a reduction of 40% (64). In
this trial, oral ZDV-3TC administered solely during
the intrapartum period was not effective in lowering
transmission. Another study in Uganda (HIVNET 012), again
in a breastfeeding population, demonstrated that a single
200-mg oral dose of nevirapine given to the mother at onset
of labor combined with a single 2-mg/kg oral dose given to
her infant at age 48–72 hours reduced transmission by nearly
50% compared with a very short regimen of ZDV given orally
during labor and to the infant for 1 week (65). Transmission
at age 6 weeks was 12% in the nevirapine group compared
with 21% in the ZDV group. A subsequent trial in South
Africa demonstrated similar transmission rates with a modi-
fied HIVNET 012 nevirapine regimen (nevirapine given to
the woman as a single dose during labor with a second dose at
48 hours postpartum, and a single dose to the infant at age
48 hours) compared with the PETRA regimen of oral ZDV-
3TC during labor and for 1 week after delivery to the mother
and infant (66). Transmission rates at age 8 weeks were 13.3%
in the nevirapine arm and 10.9% in the ZDV-3TC arm.
Two clinical trials have suggested that the addition of the
HIVNET 012 single-dose nevirapine regimen to short-course
ZDV may provide increased efficacy in reducing perinatal
transmission. A study of nonbreastfeeding women in
Thailand compared a short-course ZDV regimen (starting at
28 weeks’ gestation, given orally intrapartum, and for 1 week
to the infant) with two combination regimens: short-course
ZDV plus single-dose intrapartum/neonatal nevirapine, and
short-course ZDV plus intrapartum maternal nevirapine only.
In the short-course ZDV-only arm, enrollment was discon-
tinued by the Data and Safety Monitoring Board at the first
interim analysis because transmission was significantly higher
among those receiving ZDV alone compared with those
receiving the intrapartum/neonatal nevirapine combination
regimen (67). The study is continuing to enroll to allow com-
parison of the two combination arms. A second open-label
study in Cote d’Ivoire reported a 7.1% transmission rate at
age 4 weeks with administration of short-course ZDV (start-
ing at 36 weeks, given orally intrapartum, and for 1 week to
the infant) combined with single-dose intrapartum/neonatal
nevirapine. This was lower than for a nonconcurrent historical
control group receiving ZDV alone (68).
In contrast to these studies, which evaluated combining
single-dose nevirapine with short-course ZDV, a study in the
United States, Europe, Brazil, and the Bahamas (PACTG 316)
evaluated whether the addition of the HIVNET 012 single-
dose nevirapine regimen to standard antiretroviral therapy (at
minimum the 3-part full ZDV regimen) would provide addi-
tional benefits in lowering transmission. In this study, 1,506
pregnant women with HIV-1 infection who were receiving
antiretroviral therapy (77% were receiving combination
antiretroviral regimens) were randomized to receive a single
dose of nevirapine or nevirapine placebo at onset of labor, and
their infants received a single dose (according to the maternal
randomization) at age 48 hours. Transmission was not signifi-
cantly different between groups, occurring in 1.6% of women
in the placebo group and 1.4% among women in the
nevirapine group (69).
Certain data indicate that postexposure antiretroviral pro-
phylaxis of infants whose mothers did not receive antepartum
or intrapartum antiretroviral drugs might provide some pro-
tection against transmission. Although data from some epide-
miologic studies do not support efficacy of postnatal ZDV
alone, other data demonstrate efficacy if ZDV is started rap-
idly following birth (6,70,71). In a study from North
Carolina, the rate of infection among HIV-1–exposed infants
who received only postpartum ZDV chemoprophylaxis was
similar to that observed among infants who received no ZDV
chemoprophylaxis (6). However, another epidemiologic study
from New York State determined that administration of ZDV
to the neonate for 6 weeks was associated with a significant
reduction in transmission if the drug was initiated within 24
hours of birth (the majority of infants started within 12 hours)
(70,71). Consistent with a possible preventive effect of rapid
postexposure prophylaxis, a retrospective case-control study
of health-care workers from the United States, France, and
the United Kingdom who had nosocomial exposure to
HIV-1–infected blood determined that postexposure use of
ZDV was associated with reduced odds of contracting HIV-1
(adjusted odds ratio = 0.2; 95% CI = 0.1–0.6) (72). Several
ongoing clinical trials are attempting to determine the opti-
mal postexposure antiretroviral prophylaxis regimen for
infants.
Perinatal HIV-1 Transmission and Maternal
HIV-1 RNA Copy Number
The correlation of HIV-1 RNA levels with risk for disease
progression in nonpregnant infected adults suggests that HIV-1
RNA should be monitored during pregnancy at least as often
as recommended for persons who are not pregnant (i.e., every
3 to 4 months or approximately once each trimester). In addi-
tion, HIV-1 RNA levels should be evaluated at 34–36 weeks
of gestation to allow discussion of options for mode of deliv-
ery based on HIV-1 RNA results and clinical circumstances.
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Although no data indicate that pregnancy accelerates HIV-1
disease progression, longitudinal measurements of HIV-1 RNA
levels during and after pregnancy have been evaluated in only
a limited number of prospective cohort studies. In one cohort
of 198 HIV-1–infected women, plasma HIV-1 RNA levels
were higher at 6 months postpartum than during pregnancy
in many women; this increase was observed in women regard-
less of ZDV use during and after pregnancy (73).
Initial data regarding the correlation of viral load with risk
for perinatal transmission were conflicting, with some studies
suggesting an absolute correlation between HIV-1 RNA copy
number and risk of transmission (74). However, although
higher HIV-1 RNA levels have been observed among women
who transmitted HIV-1 to their infants, overlap in HIV-1 RNA
copy number has been observed in women who transmitted
and those who did not transmit the virus. Transmission has
been observed across the entire range of HIV-1 RNA levels
(including in women with HIV-1 RNA copy number below
the limit of detection of the assay), and the predictive value of
RNA copy number for transmission in an individual woman
has been relatively poor (73,75,76). In PACTG 076, antenatal
maternal HIV-1 RNA copy number was associated with HIV-1
transmission in women receiving placebo. In women receiv-
ing ZDV, the relationship was markedly attenuated and no
longer statistically significant (52). An HIV-1 RNA threshold
below which there was no risk for transmission was not iden-
tified; ZDV was effective in reducing transmission regardless
of maternal HIV-1 RNA copy number (52,77).
More recent data from larger numbers of ZDV-treated
infected pregnant women indicate that HIV-1 RNA levels cor-
relate with risk of transmission even among women treated
with antiretroviral agents (62,78–80). Although the risk for
perinatal transmission in women with HIV-1 RNA below the
level of assay quantitation appears to be extremely low, trans-
mission from mother to infant has been reported among
women with all levels of maternal HIV-1 RNA. Additionally,
although HIV-1 RNA may be an important risk factor for
transmission, other factors also appear to play a role (80–82).
Although there is a general correlation between viral load in
plasma and in the genital tract, discordance has also been
reported, particularly between HIV-1 proviral load in blood
and genital secretions (83–86). If exposure to HIV-1 in the
maternal genital tract during delivery is a risk factor for peri-
natal transmission, plasma HIV-1 RNA levels might not
always be an accurate indicator of risk. Long-term changes in
one compartment (such as can occur with antiretroviral treat-
ment) may or may not be associated with comparable changes
in other body compartments. Further studies are needed to
determine the effect of antiretroviral drugs on genital tract
viral load and the association of such effects on the risk of
perinatal HIV-1 transmission. In the short-course ZDV trial
in Thailand, plasma and cervicovaginal HIV-1 RNA levels
were reduced by ZDV treatment, and each independently
correlated with perinatal transmission (87). The full ZDV
chemoprophylaxis regimen, alone or in combination with
other antiretroviral agents, including intravenous ZDV dur-
ing delivery and the administration of ZDV to the infant for
the first 6 weeks of life,  should be discussed with and offered
to all infected pregnant women regardless of their HIV-1 RNA
level.
Results of epidemiologic and clinical trials suggest that
women receiving highly active antiretroviral regimens that
effectively reduce HIV-1 RNA to <1,000 copies/mL or unde-
tectable levels have very low rates of perinatal transmission
(27,61,69,88). However, since transmission can occur even at
low or undetectable HIV-1 RNA copy numbers, RNA levels
should not be a determining factor when deciding whether to
use ZDV for chemoprophylaxis. Additionally, the efficacy of
ZDV is not solely related to lowering viral load. In one study
of 44 HIV-1–infected pregnant women, ZDV was effective
in reducing transmission despite minimal effect on HIV-1
RNA levels (89). These results are similar to those observed in
PACTG 076 (52). Antiretroviral prophylaxis reduces trans-
mission even among women with HIV-1 RNA levels <1,000
copies/mL (90). Therefore, at a minimum, ZDV prophylaxis
should be given even to women who have a very low or
undetectable plasma viral load.
Preconception Counseling
and Care for HIV-1–Infected Women
of Childbearing Age
Many women infected with HIV-1 (nearly 60% in some
centers) enter pregnancy with a known diagnosis, and nearly
half of these women enter the first trimester of pregnancy
receiving treatment with single or multiagent antiretroviral
therapy (91). Additionally, as many as 40% of women who
have begun antiretroviral therapy before their pregnancy might
require adjustment of their therapeutic regimen during their
pregnancy course.
The American College of Obstetrics and Gynecology advo-
cates extending to all women of childbearing age the opportu-
nity to receive preconception counseling as a component of
routine primary medical care. It is recognized that >40% of
pregnancies may be unintended and that the diagnosis of preg-
nancy most frequently occurs late in the first trimester when
organogenesis is nearly completed. Preconception care can
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identify risk factors for adverse maternal or fetal outcome (e.g.,
age, diabetes, hypertension), provide education and counsel-
ing targeted to the patient’s individual needs, and treat or sta-
bilize medical conditions before conception to optimize
maternal and fetal outcomes (92).
For women with HIV-1 infection, preconception care must
also focus on maternal infection status, viral load, immune
status, and therapeutic regimen as well as education regarding
perinatal transmission risks and prevention strategies,
expectations for the child’s future, and, where desired, effec-
tive contraception until the optimal maternal health status for
pregnancy is achieved.
The following components of preconception counseling are
recommended for HIV-1–infected women:
• selection of effective and appropriate contraceptive meth-
ods to reduce the likelihood of unintended pregnancy;
• education and counseling about perinatal transmission
risks, strategies to reduce those risks, and potential effects
of HIV-1 or treatment on pregnancy course and outcomes;
• initiation or modification of antiretroviral therapy:
— avoid agents with potential reproductive toxicity for
the developing fetus (e.g., efavirenz, hydroxyurea) (20),
— choose agents effective in reducing the risk of perinatal
HIV-1 transmission,
— attain a stable, maximally suppressed maternal viral
load,
— evaluate and control for therapy-associated side effects
that may adversely affect maternal/fetal health out-
comes (e.g., hyperglycemia, anemia, hepatic toxicity),
• evaluation and appropriate prophylaxis for opportunistic
infections and administration of medical immunizations
(e.g., influenza, pneumococcal, or hepatitis B vaccines) as
indicated;
• optimization of maternal nutritional status;
• institution of the standard measures for preconception
evaluation and management (e.g., assessment of repro-
ductive and familial genetic history, screening for infec-
tious diseases/sexually transmitted diseases, and initiation
of folic acid supplementation);
• screening for maternal psychological and substance abuse
disorders; and
• planning for perinatal consultation if desired or indicated.
HIV-1–infected women of childbearing potential receive pri-
mary health-care services in various clinical settings, e.g., family
planning, family medicine, internal medicine, obstetrics/
gynecology. It is imperative that primary health-care provid-
ers consider the fundamental principles of preconception coun-
seling an integral component of comprehensive primary health
care for improving maternal/child health outcomes.
General Principles Regarding
the Use of Antiretroviral Agents
in Pregnancy
Medical care of the HIV-1–infected pregnant woman
requires coordination and communication between the HIV
specialist caring for the woman when she is not pregnant and
her obstetrician. Decisions regarding use of antiretroviral drugs
during pregnancy should be made by the woman after discus-
sion with her health-care provider about the known and
unknown benefits and risks of therapy. Initial evaluation of
an infected pregnant woman should include an assessment of
HIV-1 disease status and recommendations regarding
antiretroviral treatment or alteration of her current anti-
retroviral regimen.
This assessment should include the following:
• evaluation of the degree of existing immunodeficiency
determined by CD4+ count;
• risk for disease progression as determined by the level of
plasma RNA;
• history of prior or current antiretroviral therapy;
• gestational age; and
• supportive care needs.
Decisions regarding initiation of therapy should be the same
for women who are not currently receiving antiretroviral
therapy and for women who are not pregnant, with the addi-
tional consideration of the potential impact of such therapy
on the fetus and infant (14). Similarly, for women currently
receiving antiretroviral therapy, decisions regarding alterations
in therapy should involve the same considerations as those
used for women who are not pregnant. The three-part ZDV
chemoprophylaxis regimen, alone or in combination with
other antiretroviral agents, should be discussed with and
offered to all infected pregnant women to reduce the risk for
perinatal HIV-1 transmission.
Decisions regarding the use and choice of antiretroviral drugs
during pregnancy are complex; several competing factors
influencing risk and benefit must be weighed. Discussion
regarding the use of antiretroviral drugs during pregnancy
should include the following:
• what is known and not known about the effects of such
drugs on the fetus and newborn, including lack of long-
term outcome data on the use of any of the available
antiretroviral drugs during pregnancy;
• what treatment is recommended for the health of the HIV-1–
infected woman; and
• the efficacy of ZDV for reduction of perinatal HIV-1
transmission.
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Results from preclinical and animal studies and available
clinical information about use of the various antiretroviral
agents during pregnancy also should be discussed (20). The
hypothetical risks of these drugs during pregnancy should be
placed in perspective with the proven benefit of antiretroviral
therapy for the health of the infected woman and the benefit
of ZDV chemoprophylaxis for reducing the risk for HIV-1
transmission to her infant.
Discussion of treatment options should be noncoercive, and
the final decision regarding use of antiretroviral drugs is the
responsibility of the woman. Decisions regarding use and
choice of antiretroviral drugs for persons who are not preg-
nant are becoming increasingly complicated as the standard
of care moves toward simultaneous use of multiple
antiretroviral drugs to suppress viral replication below detect-
able limits. These decisions are further complicated in preg-
nancy because the long-term consequences for the infant who
has been exposed to antiretroviral drugs in utero are unknown.
A woman’s decision to refuse treatment with ZDV or other
drugs should not result in punitive action or denial of care.
Further, use of ZDV alone should not be denied to a woman
who wishes to minimize exposure of the fetus to other
antiretroviral drugs and therefore, after counseling, chooses
to receive only ZDV during pregnancy to reduce the risk for
perinatal transmission.
A long-term treatment plan should be developed after dis-
cussion between the patient and the health-care provider and
should emphasize the importance of adherence to any pre-
scribed antiretroviral regimen. Depending on individual cir-
cumstances, provision of support services, mental health
services, and drug abuse treatment may be required. Coordi-
nation of services among prenatal care providers, primary care
and HIV-1 specialty care providers, mental health and drug
abuse treatment services, and public assistance programs is
essential to ensure adherence of the infected woman to
antiretroviral treatment regimens.
General counseling should include what is known regard-
ing risk factors for perinatal transmission. Cigarette smoking,
illicit drug use, and unprotected sexual intercourse with mul-
tiple partners during pregnancy have been associated with risk
for perinatal HIV-1 transmission (93–97), and discontinuing
these practices might reduce this risk. In addition, CDC rec-
ommends that infected women in the United States refrain
from breastfeeding to avoid postnatal transmission of HIV-1
to their infants through breast milk (3,98); these recommen-
dations also should be followed by women receiving
antiretroviral therapy. Passage of antiretroviral drugs into breast
milk has been evaluated for only a few antiretroviral drugs.
ZDV, 3TC, and nevirapine can be detected in the breast milk
of women, and ddI, d4T, abacavir, delavirdine, indinavir,
ritonavir, saquinavir and amprenavir can be detected in the
breast milk of lactating rats. Limited data are available regard-
ing either the efficacy of antiretroviral therapy for the preven-
tion of postnatal transmission of HIV-1 through breast milk
or the toxicity of long-term antiretroviral exposure of the
infant through breast milk.
Women who must temporarily discontinue therapy because
of pregnancy-related hyperemesis should not resume therapy
until sufficient time has elapsed to ensure that the drugs will
be tolerated. To reduce the potential for emergence of resis-
tance, if therapy requires temporary discontinuation for any





The following recommendations for use of anti-
retroviral chemoprophylaxis to reduce the risk for perinatal
transmission are based on situations that may be commonly
encountered in clinical practice (Box 1), with relevant consid-
erations highlighted in the subsequent discussion sections.
These recommendations are only guidelines, and flexibility
should be exercised according to the patient’s individual cir-
cumstances. In the 1994 recommendations (2), six clinical
situations were delineated on the basis of maternal CD4+
count, weeks of gestation, and prior antiretroviral use.
Because current data indicate that the PACTG 076 ZDV regi-
men also is effective for women with advanced disease, low
CD4+ count, and prior ZDV therapy, clinical situations based
on CD4+ count and prior ZDV use are not presented. Addi-
tionally, because data indicate that most transmission occurs
near the time of or during delivery, ZDV chemoprophylaxis
is recommended regardless of weeks of gestation; thus, clini-
cal situations based on weeks of gestation also are not
presented.
The antenatal dosing regimen in PACTG 076 (100 mg
administered orally five times daily) (Table 1) was selected on
the basis of the standard ZDV dosage for adults at the time of
the study. However, recent data have indicated that adminis-
tration of ZDV three times daily will maintain intracellular
ZDV triphosphate at levels comparable with those observed
with more frequent dosing (99–101). Comparable clinical
response also has been observed in some clinical trials among
persons receiving ZDV twice daily (102–104). Thus, the cur-
rent standard ZDV dosing regimen for adults is 200 mg three
times daily, or 300 mg twice daily. Because the mechanism by
which ZDV reduces perinatal transmission is not known, these
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BOX 1. Clinical situations and recommendations for use of antiretroviral drugs to reduce perinatal human
immunodeficiency virus type 1 (HIV-1) transmission
1. HIV-1–infected pregnant women who have not
received prior antiretroviral therapy
• Pregnant women with HIV-1 infection must receive
standard clinical, immunologic, and virologic evalu-
ation. Recommendations for initiation and choice of
antiretroviral therapy should be based on the same
parameters used for persons who are not pregnant,
although the known and unknown risks and benefits
of such therapy during pregnancy must be consid-
ered and discussed.
• The three-part zidovudine (ZDV) chemoprophylaxis
regimen, initiated after the first trimester, should be
recommended for all pregnant women with HIV-1
infection regardless of antenatal HIV-1 RNA copy
number to reduce the risk for perinatal transmission.
• The combination of ZDV chemoprophylaxis with
additional antiretroviral drugs for treatment of HIV-1
infection is recommended for infected women whose
clinical, immunologic, or virologic status requires
treatment or whose HIV-1 RNA is >1,000 copies/
mL regardless of clinical or immunologic status.
• Women who are in the first trimester of pregnancy
may consider delaying initiation of therapy until
after 10–12 weeks’ gestation.
2. HIV-1–infected women receiving antiretroviral
therapy during the current pregnancy
• HIV-1 infected women receiving antiretroviral
therapy whose pregnancy is identified after the first
trimester should continue therapy. ZDV should be a
component of the antenatal antiretroviral treatment
regimen after the first trimester whenever possible,
although this may not always be feasible.
• Women receiving antiretroviral therapy whose preg-
nancy is recognized during the first trimester should
be counseled regarding the benefits and potential risks
of antiretroviral administration during this period,
and continuation of therapy should be considered. If
therapy is discontinued during the first trimester, all
drugs should be stopped and reintroduced simulta-
neously to avoid the development of drug resistance.
• Regardless of the antepartum antiretroviral regimen,
ZDV administration is recommended during the
intrapartum period and for the newborn.
3. HIV-1–infected women in labor who have had no
prior therapy
• Several effective regimens are available for women
who have had no prior therapy (Table 3):
— a single dose nevirapine at the onset of labor
followed by a single dose of nevirapine for the
newborn at age 48 hours,
— oral ZDV and lamivudine (3TC) during labor,
followed by 1 week of oral ZDV-3TC for the
newborn,
— intrapartum intravenous ZDV followed by
6 weeks of ZDV for the newborn, or
— the 2-dose nevirapine regimen combined with
intrapartum intravenous ZDV and 6 weeks of
ZDV for the newborn.
• In the immediate postpartum period, the woman
should have appropriate assessments (e.g., CD4+
T-lymphocyte count and HIV-1 RNA copy num-
ber) to determine whether antiretroviral therapy is
recommended for her own health.
4. Infants born to mothers who have received
no antiretroviral therapy during pregnancy or
intrapartum
• The 6-week neonatal component of the ZDV
chemoprophylactic regimen should be discussed
with the mother and offered for the newborn.
• ZDV should be initiated as soon as possible after
delivery, preferably within 6–12 hours of birth.
• Some clinicians might use ZDV in combination with
other antiretroviral drugs, particularly if the mother
is known or suspected to have ZDV-resistant virus.
However, the efficacy of this approach for preven-
tion of transmission is unknown, and appropriate
dosing regimens for neonates are incompletely
defined.
• In the immediate postpartum period, the woman
should undergo appropriate assessments (e.g., CD4+
count and HIV-1 RNA copy number) to determine
if antiretroviral therapy is required for her own
health. The infant should undergo early diagnostic
testing so that if he or she is HIV infected, treat-
ment can be initiated as soon as possible.
Note: Discussion of treatment options and recommendations should be noncoercive, and the final decision regarding use of antiretroviral
drugs is the responsibility of the woman. A decision to not accept treatment with ZDV or other drugs should not result in punitive
action or denial of care. Use of ZDV should not be denied to a woman who wishes to minimize exposure of the fetus to other antiretroviral
drugs and who therefore chooses to receive only ZDV during pregnancy to reduce the risk for perinatal transmission.
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dosing regimens may not have equivalent efficacy to that
observed in PACTG 076. However, a regimen of two or three
times daily is expected to increase adherence to the regimen.
The recommended ZDV dosage for infants was derived from
pharmacokinetic studies performed among full-term infants
(105). ZDV is primarily cleared through hepatic
glucuronidation to an inactive metabolite. The glucuronidation
metabolic enzyme system is immature in neonates, leading to
prolonged ZDV half-life and clearance compared with older
infants (ZDV half-life: 3.1 hours versus 1.9 hours; clearance:
10.9 versus 19.0 mL/minute/kg body weight, respectively).
Because premature infants have even greater immaturity in
hepatic metabolic function than full-term infants, further pro-
longation of clearance may be expected. In a study of 15 pre-
mature infants who were at 26–33 weeks’ gestation and who
received different ZDV dosing regimens, mean ZDV half-life
was 7.2 hours and mean clearance was 2.5 mL/minute/kg body
weight during the first 10 days of life (106). At a mean age of
18 days, a decrease in half-life (4.4 hours) and increase in clear-
ance (4.3 mL/minute/kg body weight) were found. The
appropriate ZDV dosage for premature infants has not been
defined but is being evaluated in a phase I clinical trial among
premature infants <34 weeks’ gestation. The dosing regimen
being studied is 1.5 mg/kg body weight orally or intravenously
every 12 hours for the first 2 weeks of life; for infants aged





1. HIV-1–infected pregnant women who have
not received prior antiretroviral therapy
Recommendation. Pregnant women with HIV-1 infection
must receive standard clinical, immunologic, and virologic
evaluation. Recommendations for initiation and choice of
antiretroviral therapy should be based on the same parameters
used for persons who are not pregnant, although the known
and unknown risks and benefits of such therapy during preg-
nancy must be considered and discussed. The three-part ZDV
chemoprophylaxis regimen, initiated after the first trimester,
should be recommended for all pregnant women with HIV-1
infection regardless of antenatal HIV-1 RNA copy number to
reduce the risk for perinatal transmission. The combination
of ZDV chemoprophylaxis with additional antiretroviral drugs
for treatment of HIV-1 infection is recommended for infected
women whose clinical, immunologic, or virologic status
requires treatment or whose HIV-1 RNA is >1,000 copies/
mL regardless of their clinical or immunologic status. Women
who are in the first trimester of pregnancy may consider
delaying initiation of therapy until after 10–12 weeks’
gestation.
Discussion. When ZDV is administered in the three-part
PACTG 076 regimen, perinatal transmission is reduced by
approximately 70%. Although the mechanism by which ZDV
reduces transmission is not known, protection is likely multi-
factorial. Preexposure prophylaxis of the infant is provided by
passage of ZDV across the placenta so that inhibitory levels of
the drug are present in the fetus during the birth process.
Although placental passage of ZDV is excellent, that of other
antiretroviral drugs is variable (Table 2). Therefore, when com-
bination antiretroviral therapy is initiated during pregnancy,
ZDV should be included as a component of antenatal therapy
whenever possible. Because the mechanism by which ZDV
reduces transmission is not known, the intrapartum and new-
born ZDV components of the chemoprophylactic regimen
should be administered to reduce perinatal HIV-1 transmis-
sion. If a woman does not receive ZDV as a component of her
antenatal antiretroviral regimen, intrapartum and newborn
ZDV should still be recommended.
Because of the evolving and complex nature of the manage-
ment of HIV-1 infection, a specialist with experience in the
treatment of pregnant women with HIV-1 infection should
be involved in their care. Women should be informed that
potent combination antiretroviral regimens have substantial
benefit for their own health and may provide enhanced pro-
tection against perinatal transmission. Several studies have
indicated that for women with low or undetectable HIV-1
RNA levels (e.g., <1,000 copies/mL) rates of perinatal
transmission are extremely low, particularly when they have
received antiretroviral therapy (61,78,79). However, there is
no threshold below which lack of transmission can be assured,
and the long-term effects of in utero exposure to multiple
antiretroviral drugs are unknown. Decisions regarding the use
and choice of an antiretroviral regimen should be individual-
ized based on discussion with the woman about the following
factors:
• her risk for disease progression and the risks and benefits
of delaying initiation of therapy;
• possible benefit of lowering viral load for reducing peri-
natal transmission;
• potential drug toxicities and interactions with other drugs
• the need for strict adherence to the prescribed drug sched-
ule to avoid the development of drug resistance;
• unknown long-term effects of in utero drug exposure on
the infant; and
• preclinical, animal, and clinical data relevant to use of the
currently available antiretroviral agents during pregnancy.
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Because the period of organogenesis (when the fetus is most
susceptible to potential teratogenic effects of drugs) is during
the first 10 weeks of gestation and the risks of antiretroviral
therapy during that period are unknown, women in the first
trimester of pregnancy might wish to delay initiation of therapy
until after 10–12 weeks’ gestation. This decision should be
carefully considered by the health-care provider and the
patient; a discussion should include an assessment of the
woman’s health status, the benefits and risks of delaying ini-
tiation of therapy for several weeks, and the fact that most
perinatal HIV-1 transmission likely occurs late in pregnancy
or during delivery. Treatment with efavirenz should be avoided
during the first trimester because significant teratogenic
effects in rhesus macaques were seen at drug exposures similar
to those representing human exposure (Table 2) (20). Hydrox-
yurea is a potent teratogen in a variety of animal species and
should also be avoided during the first trimester.
When initiation of antiretroviral therapy is considered
optional on the basis of current guidelines for treatment of
nonpregnant persons (14), infected pregnant women should
be counseled regarding the potential benefits of standard com-
bination therapy and should be offered such therapy, includ-
ing the three-part ZDV chemoprophylaxis regimen. Although
such women are at low risk for clinical disease progression if
combination therapy is delayed, antiretroviral therapy that suc-
cessfully reduces HIV-1 RNA to levels <1,000 copies/mL may
substantially lower the risk of perinatal HIV-1 transmission
and lessen the need for consideration of elective cesarean
delivery as an intervention to reduce transmission risk.
When combination therapy is administered, the regimen
should be chosen from those recommended for nonpregnant
adults (14). Dual nucleoside analog therapy without the
addition of either a protease inhibitor or nonnucleoside
reverse transcriptase inhibitor is not recommended for non-
pregnant adults because of the potential for inadequate viral
suppression and rapid development of resistance (107). For
pregnant women not meeting the criteria for antiretroviral
therapy for their own health, and receiving antiretroviral drugs
only for prevention of perinatal transmission (e.g., those with
HIV-1 RNA <1,000 copies/mL), dual nucleoside therapy may
be considered in selected circumstances. If combination
therapy is given principally to reduce perinatal transmission
and would have been optional if the woman were not preg-
nant, consideration may be given to discontinuing therapy
postnatally, with the option to reinitiate treatment according
to standard criteria for nonpregnant women. If drugs are dis-
continued postnatally, all drugs should be stopped simulta-
neously. Discussion regarding the decision to continue or stop
combination therapy postpartum should occur before begin-
ning therapy during pregnancy.
Antiretroviral prophylaxis has been beneficial in preventing
perinatal transmission even for infected pregnant women with
HIV-1 RNA levels <1,000 copies/mL. In a meta-analysis of
factors associated with perinatal transmission among women
whose infants were infected despite the women’s having HIV-1
RNA <1,000 copies/mL at or near delivery, transmission was
only 1.0% among women receiving antenatal antiretroviral
therapy (primarily ZDV alone) compared with 9.8% among
those receiving no antenatal therapy (90). Therefore, use of
antiretroviral prophylaxis is recommended for all pregnant
women with HIV-1 infection regardless of antenatal HIV-1
RNA level.
The time-limited use of ZDV alone during pregnancy for
chemoprophylaxis against perinatal transmission is controver-
sial. Standard combination antiretroviral regimens for treat-
ment of HIV-1 infection should be discussed and should be
offered to all pregnant women with HIV-1 infection regard-
less of viral load; they are recommended for all pregnant women
with HIV-1 RNA levels >1,000 copies/mL. Some women may
wish to restrict exposure of their fetus to antiretroviral drugs
during pregnancy and still reduce the risk of transmitting HIV-1
to their infant. Additionally, for women with HIV-1 RNA
levels <1,000 copies/mL, time-limited use of ZDV during the
second and third trimesters of pregnancy is less likely to
induce the development of resistance because of the limited
viral replication existing in the patient and the time-limited
exposure to the antiretroviral drug. For example, the develop-
ment of ZDV resistance was unusual among the healthy popu-
lation of women who participated in PACTG 076 (108). The
use of ZDV chemoprophylaxis alone (or, in selected circum-
stances, dual nucleosides) during pregnancy might be an
appropriate option for these women.
2. HIV-1–infected women receiving
antiretroviral therapy during the current
pregnancy
Recommendation. HIV-1 infected women receiving
antiretroviral therapy whose pregnancy is identified after the
first trimester should continue therapy. ZDV should be a com-
ponent of the antenatal antiretroviral treatment regimen after
the first trimester whenever possible, although this may not
always be feasible. Women receiving antiretroviral therapy
whose pregnancy is recognized during the first trimester should
be counseled regarding the benefits and potential risks of
antiretroviral administration during this period, and continu-
ation of therapy should be considered. If therapy is discontin-
ued during the first trimester, all drugs should be stopped and
reintroduced simultaneously to avoid the development of drug
resistance. Regardless of the antepartum antiretroviral
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regimen, ZDV administration is recommended during the
intrapartum period and for the newborn.
Discussion. Women who have been receiving antiretroviral
treatment for their HIV-1 infection should continue treat-
ment during pregnancy. Discontinuation of therapy could lead
to an increase in viral load, which could result in decline in
immune status and disease progression as well as adverse
consequences for both the fetus and the woman.
Although ZDV should be a component of the antenatal
antiretroviral treatment whenever possible, there may be cir-
cumstances, such as the occurrence of significant ZDV-related
toxicity, when this is not feasible. Additionally, women
receiving an antiretroviral regimen that does not contain ZDV
but who have HIV-1 RNA levels that are consistently very
low or undetectable (e.g., <1,000 copies/mL) have a very low
risk of perinatal transmission (61), and there may be concerns
that the addition of ZDV to the current regimen could
compromise adherence to treatment.
The maternal antenatal antiretroviral treatment regimen
should be continued on schedule as much as possible during
labor to provide maximal virologic effect and to minimize the
chance of development of drug resistance. If a woman has not
received ZDV as a component of her antenatal therapeutic
antiretroviral regimen, intravenous ZDV should still be
administered during the intrapartum period whenever feasible.
ZDV and d4T should not be administered together because
of potential pharmacologic antagonsim; options for women
receiving oral d4T as part of their antenatal therapy include
either continuation of oral d4T during labor without intrave-
nous ZDV or withholding oral d4T during the period of
intravenous ZDV administration during labor. Additionally,
the infant should receive the standard 6-week course of ZDV.
For women with suboptimal suppression of HIV-1 RNA
(i.e., >1,000 copies/mL) near the time of delivery despite hav-
ing received prenatal ZDV prophylaxis with or without com-
bination antiretroviral therapy, it is not known if
administration of additional antiretroviral drugs during labor
and delivery provides added protection against perinatal trans-
mission. In the HIVNET 012 study among Ugandan women
who had not received antenatal antiretroviral therapy, a 2-dose
nevirapine regimen (single dose to the woman at the onset of
labor and single dose to the infant at age 48 hours) signifi-
cantly reduced perinatal transmission compared with a very
short intrapartum/1 week postpartum ZDV regimen (65). For
women in the United States, Europe, Brazil, and the Bahamas
receiving antenatal antiretroviral therapy, addition of the
2-dose nevirapine regimen did not result in lower transmis-
sion rates (69). Given the lack of further reduction of trans-
mission with nevirapine added to one of the standard
antepartum regimens used in developed countries and the
potential development of nevirapine resistance (See
Antiretroviral Drug Resistance and Resistance Testing in Preg-
nancy), addition of nevirapine during labor for women
already receiving antiretroviral therapy is not recommended
in the United States.
Women receiving antiretroviral therapy may realize they are
pregnant early in gestation and want to consider temporarily
stopping antiretroviral treatment until after the first trimester
because of concern for potential teratogenicity. Data are
insufficient to support or refute the teratogenic risk of
antiretroviral drugs when administered during the first
10 weeks of gestation; certain drugs are of more concern than
others (Table 2) (20). The decision to continue therapy dur-
ing the first trimester should be carefully considered by the
clinician and the pregnant woman. Discussions should include
considerations such as gestational age of the fetus; the woman’s
clinical, immunologic, and virologic status; and the known
and unknown potential effects of the antiretroviral drugs on
the fetus. If antiretroviral therapy is discontinued during the
first trimester, all agents should be stopped and restarted
simultaneously in the second trimester to avoid the develop-
ment of drug resistance. No data are available to address
whether temporary discontinuation of therapy is harmful for
the woman or fetus.
Health-care providers might consider administering ZDV
in combination with other antiretroviral drugs to newborns
of women with a history of prior antiretroviral therapy, par-
ticularly in situations in which the woman is infected with
HIV-1 with documented high-level ZDV resistance, has had
disease progression while receiving ZDV, or has had extensive
prior ZDV monotherapy. The efficacy of this approach is
unknown but would be analogous to the use of multiple agents
for postexposure prophylaxis for adults after inadvertent
exposure. However, the appropriate dosage and short- and
long-term safety of many antiretroviral agents in the neonate
has not been established. The half-lives of ZDV, 3TC, and
nevirapine are prolonged during the neonatal period because
of immature liver metabolism and renal function, requiring
specific dosing adjustments when these agents are adminis-
tered to neonates. Optimal dosages for protease inhibitors in
the neonatal period are still under study. The infected woman
should be counseled regarding the theoretical benefit of com-
bination antiretroviral drugs for the neonate, potential risks,
and available data on appropriate dosing. She should also be
informed that using antiretroviral drugs in addition to ZDV
for prophylaxis of newborns is of unknown efficacy in reduc-
ing risk of perinatal transmission.
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TABLE 3. Comparison of intrapartum/postpartum regimens for HIV-1–infected women in labor who have had no prior antiretroviral
therapy
* ZDV, zidovudine; CI, confidence interval; 3TC, lamivudine.
†
If the mother received nevirapine less than 1 hour before delivery, the infant should be given 2 mg/kg oral nevirapine as soon as possible after birth and
again at 48–72 hours.
3. HIV-1–Infected Women in Labor Who Have
Had No Prior Therapy
Recommendation. Several effective regimens are available
for intrapartum therapy for women who have had no prior
therapy (Table 3):
• a single dose of nevirapine at onset of labor followed by a
single dose of nevirapine for the newborn at age 48 hours;
• oral ZDV and 3TC during labor, followed by 1 week of
oral ZDV-3TC for the newborn;
• intrapartum intravenous ZDV followed by 6 weeks of
ZDV for the newborn; and
• the 2-dose nevirapine regimen combined with intrapar-
tum intravenous ZDV and 6 weeks of ZDV for the
newborn.
In the immediate postpartum period, the woman should
have appropriate assessments (e.g., CD4+ count and HIV-1
RNA copy number) to determine whether antiretroviral
therapy is recommended for her own health.
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Discussion. Although intrapartum antiretroviral medica-
tions will not prevent perinatal transmission that occurs
before labor, most transmission occurs near to or during labor
and delivery. Preexposure prophylaxis for the fetus can be pro-
vided by giving the mother a drug that rapidly crosses the
placenta to produce systemic antiretroviral drug levels in the
fetus during intensive exposure to HIV-1 in maternal genital
secretions and blood during birth.
Several intrapartum/neonatal antiretroviral prophylaxis regi-
mens are applicable for women in labor who have had no
prior antiretroviral therapy (Table 3). Two regimens, one
using 2 doses of nevirapine (one each for the mother and
infant) and the other a combination of ZDV and 3TC, were
shown to reduce perinatal transmission in randomized clini-
cal trials among breastfeeding women, and available epide-
miologic data suggest the efficacy of a third, ZDV-only
regimen. The fourth regimen, combining ZDV with
nevirapine, is based upon theoretical considerations.
In the HIVNET 012 trial, conducted in Uganda, a regimen
consisting of a single dose of oral nevirapine given to the
woman at onset of labor and a single dose to the infant at age
48 hours was compared with oral ZDV given to the woman
every 3 hours during labor and postnatally to the infant for
7 days (Table 3). At age 6 weeks, the rates of transmission
were 12% (95% CI = 8%–16%) in the nevirapine arm versus
21% (95% CI = 16%–26%) in the ZDV arm, a 47% reduc-
tion (95% CI = 20%–64%) in transmission (65). No serious
short-term toxicity was observed in either group. Because no
placebo group was included, no conclusions can be drawn
regarding the efficacy of the intrapartum/1-week neonatal
ZDV regimen versus no treatment.
In the PETRA trial, conducted in Uganda, South Africa,
and Tanzania, ZDV and 3TC were administered orally intra-
partum and to the woman and infant for 7 days postnatally.
Oral ZDV and 3TC were administered at the onset of labor
and continued until delivery (Table 3). Postnatally, the woman
and infant received ZDV and 3TC every 12 hours for 7 days.
At age 6 weeks, the rates of transmission were 9% in the ZDV-
3TC arm versus 15% in the placebo arm, a 40% reduction in
transmission (64). However, no differences in transmission
were observed when oral ZDV and 3TC were administered
only during the intrapartum period (transmission of 14% in
the ZDV-3TC arm versus 15% in the placebo arm), indicat-
ing that some postexposure prophylaxis is needed, at least in
breastfeeding settings.
These clinical trials were conducted in Africa, where the
majority of women breastfeed their infants. Because HIV-1
can be transmitted by breast milk and the highest risk period
for such transmission is the first few months of life (109), the
absolute transmission rates observed in the African trials may
not be comparable to what might be observed with these regi-
mens in HIV-1–infected women in the United States, where
breastfeeding is not recommended. However, comparison of
the percentage of reduction in transmission at early timepoints
(e.g., 4–6 weeks) may be applicable. In the effective arms of
the PETRA trial, antiretroviral drugs were administered post-
natally to both the mother and the infant to reduce the risk of
early transmission through breast milk. In the United States,
administration of ZDV-3TC to the mother postnatally in
addition to the infant would not be required for prophylaxis
against transmission because HIV-1–infected women are
advised not to breastfeed their infants (although ZDV-3TC
might be indicated as part of a combination postnatal treat-
ment regimen for the woman).
Epidemiologic data from New York State indicate that
intravenous maternal intrapartum ZDV followed by oral ZDV
for 6 weeks to the infant may significantly reduce trans-
mission compared with no treatment (Table 3). Transmission
rates were 10% (95% CI = 3%–22%) with intrapartum and
neonatal ZDV compared with 27% (95% CI = 21%–33%)
without ZDV, a 62% reduction in risk (95% CI = 19%–82%)
(70,71). Similarly, in an epidemiologic study in North Caro-
lina, intravenous intrapartum and 6-week oral neonatal ZDV
treatment was associated with a transmission rate of 11%,
compared with 31% without therapy (6). However, intrapar-
tum ZDV combined with very short-term ZDV administra-
tion to infants postnatally, e.g., the 1-week postnatal infant
ZDV course in HIVNET 012 (65), has not proved effective
to date. This underscores the necessity of recommending a
full 6-week course of infant treatment when ZDV alone is
used.
No data are available to address the relative efficacy of these
three intrapartum/neonatal antiretroviral regimens for preven-
tion of transmission. In the absence of data to suggest the
superiority of one or more of the possible regimens, choice
should be based upon the specific circumstances of each
woman. The 2-dose nevirapine regimen offers the
advantage of lower cost, the possibility of directly observed
therapy and increased adherence compared with the other two
regimens. In a clinical trial (SAINT) in South Africa, which
compared the 2-dose nevirapine and the intrapartum/
postpartum ZDV-3TC regimens, no significant differences
were observed between the two regimens in terms of efficacy
in reducing transmission or in maternal and infant toxicity
(66).
It has not been determined if combining intravenous intra-
partum/6-week neonatal oral ZDV with the 2-dose nevirapine
regimen will provide additional benefit over that observed with
each regimen alone. Clinical trial data have established that
combination therapy is superior to single-drug therapy for
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treatment of persons with established infection and that
infants born to women in labor who have not received any
antiretroviral therapy are at high risk for infection. The
2-dose nevirapine regimen had no serious short-term drug-
associated toxicity in the 313 mother–infant pairs exposed to
the regimen in the HIVNET 012 trial. Nevirapine and ZDV
are synergistic in inhibiting HIV-1 replication in vitro (110),
and both nevirapine and ZDV rapidly cross the placenta to
achieve drug levels in the infant nearly equal to those in the
mother. In contrast to ZDV, nevirapine can decrease plasma
HIV-1 RNA concentration by at least 1.3 log by 7 days after a
single dose (111) and is active immediately against intracellu-
lar and extracellular virus (112). However, nevirapine resis-
tance can be induced by a single mutation at codon 181,
whereas high-level resistance to ZDV requires several muta-
tions. Nevirapine resistance mutations were detected at 6
weeks postpartum in 19% of antiretroviral naive women and
15% of women receiving antiretroviral drugs during pregnancy
who received single-dose nevirapine during labor (See
Antiretroviral Drug Resistance and Resistance Testing in
Pregnancy).
A theoretical benefit of combining the intrapartum/neonatal
ZDV and nevirapine regimens would be the efficacy of this
combination if the woman had acquired infection with HIV-1
that is resistant to either ZDV or nevirapine. Perinatal trans-
mission of antiretroviral drug-resistant virus has been reported
but appears to be unusual (6,113,114). Virus with low-level
ZDV resistance may be less likely to establish infection than
wild-type virus, and transmission may not occur even when
maternal virus has high-level ZDV resistance (114–117). Since
the prevalence of drug-resistant virus is an evolving phenom-
enon, surveillance is needed to determine this prevalence in
pregnant women over time and the risk of transmission of
resistant viral strains. The potential benefits of combination
prophylaxis with intrapartum/neonatal nevirapine and ZDV
must be weighed against the increased cost, possible problems
with nonadherence, potential short- and long-term toxicity,
including the risk of emergence of nevirapine-resistant virus,
and the lack of definitive data to show that combining the
two intrapartum/postpartum regimens offers any additional
benefit for prevention of transmission over the use of either
drug alone.
4. Infants Born to Mothers Who Have
Received No Antiretroviral Therapy During
Pregnancy or Intrapartum
Recommendation. The 6-week neonatal component of the
ZDV chemoprophylactic regimen should be discussed with
the mother and offered for the newborn. ZDV should be
initiated as soon as possible after delivery, preferably within
6–12 hours of birth. Some clinicians may use ZDV in combi-
nation with other antiretroviral drugs, particularly if the mother
is known or suspected to have ZDV-resistant virus. However,
the efficacy of this approach for prevention of transmission is
unknown, and appropriate dosing regimens for neonates are
incompletely defined. In the immediate postpartum period,
the woman should undergo appropriate assessments (e.g.,
CD4+ count and HIV-1 RNA copy number) to determine if
antiretroviral therapy is required for her own health. The
infant should undergo early diagnostic testing so that if he or
she is HIV-1 infected, treatment can be initiated as soon as
possible.
Discussion. Definitive data are not available to address
whether ZDV administered only during the neonatal period
would reduce the risk of perinatal transmission. Epidemio-
logic data from a New York State study indicate a decline in
transmission when infants were given ZDV for the first 6 weeks
of life compared with no prophylaxis (70,71). Transmission
rates were 9% (95% CI = 4.1%–17.5%) with ZDV prophy-
laxis of newborns only (initiated within 48 hours after birth)
versus 18% (95% CI = 7.7%–34.3%) with prophylaxis initi-
ated after 48 hours, and 27% (95% CI = 21%–33%) with
no ZDV prophylaxis (70). Epidemiologic data from North
Carolina did not demonstrate a benefit of ZDV for newborns
only compared with no prophylaxis (6). Transmission rates
were 27% (95% CI = 8%–55%) with prophylaxis of new-
borns only and 31% (95% CI = 24%–39%) with no prophy-
laxis. The timing of initiation of infant prophylaxis was not
defined in this study. Data from a case-control study of
postexposure prophylaxis of health-care workers who had
nosocomial percutaneous exposure to blood from HIV-1–
infected persons indicate that ZDV administration was asso-
ciated with a 79% reduction in the risk for HIV-1
seroconversion following exposure (72). Postexposure prophy-
laxis also has prevented retroviral infection in some studies
involving animals (118–120).
The interval during which benefit can be gained from
postexposure prophylaxis is undefined. When prophylaxis was
delayed beyond 48 hours after birth in the New York State
study, no efficacy could be demonstrated. For most infants in
this study, prophylaxis was initiated within 24 hours (71). Data
from studies of animals indicate that the longer the delay in
institution of prophylaxis, the less likely that infection will be
prevented. In most studies of animals, antiretroviral prophy-
laxis initiated 24–36 hours after exposure has usually not been
effective for preventing infection, although later administra-
tion has been associated with decreased viremia (118–120).
In cats, ZDV treatment initiated within the first 4 days after
challenge with feline leukemia virus afforded protection,
whereas treatment initiated 1 week postexposure did not (121).
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The relevance of these animal studies to prevention of perina-
tal HIV-1 transmission in humans is unknown. HIV-1 infec-
tion is established in most infected infants by age 1–2 weeks.
In a study of 271 infected infants, HIV-1 DNA polymerase
chain reaction (PCR) was positive in 38% of samples from
infants tested within 48 hours of birth. No substantial change
in diagnostic sensitivity was observed within the first week of
life, but detection increased rapidly during the second week
of life, reaching 93% by age 14 days (122). Initiation of
postexposure prophylaxis after age 2 days is not likely to be
efficacious in preventing transmission, and by age 14 days,
infection would already be established in most infants.
When the mother has received neither the antenatal nor
intrapartum parts of the three-part ZDV regimen, adminis-
tration of antiretroviral drugs to the newborn provides chemo-
prophylaxis only after HIV-1 exposure has already occurred.
Some clinicians view this situation as analogous to nosoco-
mial postexposure prophylaxis and may wish to provide ZDV
in combination with one or more other antiretroviral agents.
Such a decision must be accompanied by a discussion with
the woman of the potential benefits and risks of this approach
and the lack of data to address its efficacy and safety.
Antiretroviral Drug Resistance and
Resistance Testing in Pregnancy
The development of antiretroviral drug resistance is one of
the major factors leading to therapy failure in HIV-1–infected
persons. Resistant viral variants emerge under selective pres-
sure, especially with incompletely suppressive regimens,
because of the inherent mutation-prone process of reverse tran-
scription with viral replication. The administration of combi-
nation antiretroviral therapy with maximal suppression of viral
replication to undetectable levels limits the development of
antiretroviral resistance in both pregnant and nonpregnant
persons. Some have raised concern that using non-highly
active antiretroviral regimens, such as ZDV monotherapy, for
prophylaxis against perinatal transmission could result in the
development of resistance, which, in turn, could influence
perinatal transmission and limit future maternal therapeutic
options. Additionally, the general implications of antiretroviral
resistance for maternal, fetal, and newborn health are of
increasing interest as more HIV-1–infected women enter preg-
nancy with prior exposure to antiretroviral drugs.
The prevalence of antiretroviral drug resistance mutations
in virus from newly infected, therapy-naive persons has varied
by geographic area and the type of assay used (genotypic ver-
sus phenotypic) (114,123–126). In surveys from the United
States and Europe, rates of primary resistance mutations in
the reverse transcriptase gene were >10% in the majority
of studies and ranged as high as 23%. Primary resistance
mutations in the protease gene ranged from 1% to 16%, and
secondary mutations and polymorphisms of the protease gene
were very common. The presence of high-level phenotypic
resistance (>10-fold increase in 50% inhibitory concentration
[IC50]) was uncommon but tended to occur among isolates
with genotypic resistance. Lower level resistance (2.5- to 10-
fold decrease in susceptibility) was more common and tended
to occur in the absence of genotypic mutations known to confer
resistance.
The prevalence of resistance mutations during pregnancy
also varies depending on the characteristics of the population
studied. No high-level resistance to ZDV was detected at
baseline among a subset of women enrolled in PACTG 076,
all of whom had CD4+ counts >200 cells/mL and had
received no or only limited prior ZDV therapy (108). Con-
versely, among women receiving ZDV for maternal health
indications before 1994 in the Women and Infants Transmis-
sion Study (WITS), any ZDV resistance mutation was
detected in 35 (25%) of 142 isolates, and high-level ZDV
resistance was detected in 14 (10%) isolates (127). Codon
215 mutations, associated with high-level ZDV resistance, were
detected in isolates from 9.6% of 62 consecutive women in
the Swiss HIV-1 in Pregnancy Study (115). Similarly, in New
York, codon 215 mutations were detected in no isolates from
33 women who delivered before 1997 and three (9.7%) from
31 women who delivered from 1997 to 1999; mutations were
detected only among women with previous ZDV exposure
(128). Among 220 pregnant women with prior ZDV expo-
sure who were enrolled in the Perinatal AIDS Collaborative
Transmission Study, virus with primary mutations conferring
resistance to nucleoside analog drugs was observed in 17.7%,
and primary or secondary resistance mutations in 22%; none
of the women had virus containing primary nonnucleoside
resistance mutations, 2.3% had secondary nonnucleoside
resistance mutations, and 0.5% had virus with a primary
mutation conferring resistance to protease inhibitors (117).
In all these studies, women evaluated for resistance mutations
were a subset of the larger studies, chosen because of detect-
able HIV-1 RNA levels with amplifiable virus and often
because of clinical findings suggesting an increased risk of
resistance. Thus, the rate of resistance mutations in the entire
population is likely to be much lower than in the subsets.
The detection of ZDV or other resistance mutations was
not associated with an increased risk of perinatal transmission
in the PACTG 076, PACTG 185, Swiss cohort, or PACTS
studies (108,115,117,129). In the WITS substudy, detection
of ZDV resistance was not significantly associated with
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transmission on univariate analysis, but when adjusted for
duration of ruptured membranes and total lymphocyte count,
resistance mutations conferred an increased risk of transmis-
sion (127). Women in this cohort were receiving ZDV during
pregnancy for their own health (mean CD4+ count at deliv-
ery 315 cells/mL), usually without intravenous ZDV during
labor or ZDV for the infants. Factors associated with resis-
tance at delivery included ZDV use before pregnancy, higher
log HIV-1 RNA, and lower CD4+ count. Women with char-
acteristics similar to those in the WITS substudy should be
advised to take highly active antiretroviral therapy for their
own health and for prevention of perinatal transmission.
Although perinatal transmission of resistant virus has been
reported (113,130), it appears to be unusual, and it is not
clear that the presence of mutations increases the risk of trans-
mission. In the WITS substudy, when a transmitting mother
had a mixed viral population of wild-type and low-level resis-
tant virus, only the wild-type virus was found in the infant,
suggesting that virus with low-level ZDV resistance may be
less transmissible (116).
Another concern is the potential for resistance developing
in the mother during prophylaxis against perinatal transmis-
sion, which may then influence future therapy options. In
some combination antiretroviral clinical trials, patients with
previous ZDV therapy experienced less benefit from combi-
nation therapy than those who had never received prior
antiretroviral therapy (12,131). However, in these studies the
median duration of prior ZDV use was 12–20 months, and
enrolled patients had more advanced disease and lower CD4+
counts than did the population of women enrolled in PACTG
076 or those for whom initiation of therapy would be consid-
ered optional. In one study, patients with <12 months of ZDV
responded as favorably to combination therapy as those with-
out prior ZDV therapy (131). In PACTG 076, the median
duration of ZDV therapy was 11 weeks; the maximal dura-
tion of ZDV (begun at 14 weeks’ gestation) would be 6.5
months for a full-term pregnancy. Additionally, the develop-
ment of resistance should be minimized by providing highly
active antiretroviral regimens for all women during pregnancy
to suppress viral replication to undetectable levels. However,
women with low maternal HIV-1 RNA levels may choose the
PACTG 076 ZDV regimen to minimize exposure of the fetus
to antiretroviral drugs, provided their plasma HIV-1 RNA
remains very low or undetectable. Among a subset of women
from PACTG 076 (transmitters in the ZDV group, a random
selection of nontransmitters in the ZDV group, and women
with a history of prior ZDV therapy), no high-level resistance
mutations were detected at baseline or delivery, and a low-
level resistance mutation developed between baseline and
delivery in virus from one (2.6%) of 39 women (108). Data
from an analysis of PACTG 288, a follow-up study of the
women enrolled in PACTG 076 who were monitored for a
median of >4 years postpartum, indicate no substantial
differences in CD4+ count, HIV-1 RNA copy number, devel-
opment of ZDV resistance, or time to progression to AIDS or
death among women who received ZDV compared with those
who received placebo (132).
Rapid development of resistance to 3TC has been reported
among persons receiving dual nucleoside therapy without other
agents. In a small study, the M184V 3TC resistance mutation
was detectable by delivery in four (80%) of five women treated
with ZDV-3TC during pregnancy (133). In a French cohort
in which 3TC was added at 32 weeks’ gestation to the PACTG
076 ZDV regimen, among 132 samples tested from 6 weeks
postpartum, the M184V mutation was detected in 52 (39%);
the prevalence of this mutation, before receipt of 3TC, was
only 2% (27). ZDV resistance mutations included T215Y/F
in nine (7%), M41L in nine (7%), and K70R in 14 (11%). In
multivariate analyses, factors associated with detection of the
M184V mutation after delivery included lower CD4+ count,
higher HIV-1 RNA levels, and longer duration of 3TC therapy.
Thus, dual nucleoside therapy is not recommended for treat-
ment of nonpregnant persons with HIV-1 infection or preg-
nant women who fulfill criteria for initiation of antiretroviral
therapy for their own health. These 3TC resistance mutations
have also been noted in clinical trials of three drug combina-
tions including 3TC (134,135). In selected circumstances, dual
nucleoside therapy may be considered for pregnant women
who are receiving antiretroviral agents for perinatal prophy-
laxis only. The potential benefits and risks of this approach
have not been well studied, and concerns exist about the po-
tential for inadequate viral suppression and rapid development
of resistance with use of dual nucleoside treatment.
Selection of nevirapine-resistant virus has also been detected
at 6 weeks postpartum in women receiving a single dose of
nevirapine during labor. In HIVNET 012, in which
antiretroviral-naive Ugandan women received a single dose of
nevirapine during labor to prevent perinatal HIV-1 transmis-
sion, genotypic mutations associated with nevirapine
resistance were detected at 6 weeks postpartum in samples
from 21 (19%) of 111 women with detectable viral replica-
tion who received nevirapine (136). The rate of resistance was
similar among mothers whose children were or were not in-
fected. Development of resistance was associated with signifi-
cantly higher baseline viral loads and lower CD4+ counts.
Samples taken 12–24 months after delivery from a subset of
these women no longer had detectable nevirapine resistance,
suggesting that this regimen might be effective for perinatal
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prophylaxis in subsequent pregnancies. Implications concern-
ing the transient development of detectable nevirapine geno-
typic resistance mutations from single-dose nevirapine for
future maternal therapeutic options are unclear.
Further data are needed to assess the frequency of develop-
ment of resistance with single-dose intrapartum nevirapine
used alone versus with other agents such as ZDV in women
who have not received antenatal treatment. In PACTG 316,
in which single-dose nevirapine administered during labor and
to the newborn was added to the woman’s existing antiretroviral
regimen, newly detectable nevirapine-resistance mutations were
detected at 6 weeks postpartum in 14 (15%) of 95 women
who received single-dose intrapartum nevirapine and had
detectable HIV-1 RNA at delivery (137). The risk for devel-
opment of a new nevirapine resistance mutation did not cor-
relate with CD4+ count at delivery, HIV-1 RNA copy number,
or type of antenatal antiretroviral treatment (resistance occurred
in women receiving highly active antiretroviral therapy as well
as ZDV monotherapy). Given lack of further reduction of
transmission with nevirapine added to an established regimen
(69) and the potential development of resistance, addition of
nevirapine during labor for women already receiving
antiretroviral therapy is not recommended.
The International AIDS Society-USA Panel and
EuroGuidelines Group for HIV-1 Resistance recommend that
all pregnant women with detectable HIV-1 RNA levels
undergo resistance testing, even if they are antiretroviral
naive, to try to maximize the response to antiretroviral drugs
in pregnancy, although data to support an improved maternal
outcome or reduced risk of perinatal transmission with rou-
tine resistance testing are not available (138,139). Until fur-
ther data are available, resistance testing foHIV-1–infecteded
pregnant women should be done for the same indications as
for nonpregnant persons:
• those with acute infection;
• those who have virologic failure with persistently detect-
able HIV-1 RNA levels while receiving antenatal therapy,
or suboptimal viral suppression after initiation of
antiretroviral therapy; or
• those with a high likelihood of having resistant virus, based
on community prevalence of resistant virus, known drug
resistance in the woman’s sex partner, or other source of
infection.
The optimal prophylactic regimen for newborns of women
with ZDV resistance is unknown. Therefore, antiretroviral
prophylaxis of the infant born to a woman with known or
suspected ZDV-resistant HIV-1 should be determined in con-
sultation with pediatric infectious disease specialists.
Recommendations related to antiretroviral drug resistance
and drug resistance testing for pregnant women with HIV-1
infection are listed here (Box 2).
Perinatal HIV-1 Transmission
and Mode of Delivery
Transmission and Mode of Delivery
Optimal medical management during pregnancy should
include antiretroviral therapy to suppress plasma HIV-1 RNA
to undetectable levels. Labor and delivery management of HIV-
1–infected pregnant women should focus on minimizing the
risk for both perinatal transmission of HIV-1 and the poten-
tial for maternal and neonatal complications.
Several studies done before viral load testing and combina-
tion antiretroviral therapy became a routine part of clinical
practice consistently showed that cesarean delivery (elective
or scheduled) performed before onset of labor and rupture of
membranes was associated with a significant decrease in perina-
tal HIV-1 transmission compared with other types of delivery,
with reductions ranging from 55% to 80%. Data regarding
transmission rates according to receipt of ZDV have been
summarized (Table 4) (140,141).
The observational data comprised individual patient infor-
mation from 15 prospective cohort studies, including more
than 7,800 mother–child pairs, analyzed in a meta-analysis
(140). In this meta-analysis, the rate of perinatal HIV-1 trans-
mission among women undergoing elective cesarean delivery
was significantly lower than that among similar women hav-
ing either nonelective cesarean or vaginal delivery, regardless
of whether they received ZDV. In an international random-
ized trial of mode of delivery, transmission was 1.8% among
women randomized to elective cesarean delivery, many of
whom received ZDV (141). Although the reduction in trans-
mission after elective cesarean section versus vaginal delivery
among women receiving ZDV in the randomized trial was
similar to that seen in untreated women, this was not statisti-
cally significant. Additionally, in both studies, nonelective
cesarean delivery (performed after onset of labor or rupture of
membranes) was not associated with a significant decrease in
transmission compared with vaginal delivery. The American
College of Obstetricians and Gynecologists’ (ACOG) Com-
mittee on Obstetric Practice, after reviewing these data, has
issued a Committee Opinion concerning route of delivery rec-
ommending consideration of scheduled cesarean delivery for
HIV-1–infected pregnant women with HIV-1 RNA levels
>1,000 copies/ml near the time of delivery (142).
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• All pregnant women should be offered highly active
antiretroviral therapy to maximally suppress viral replica-
tion, reduce the risk of perinatal transmission, and mini-
mize the risk of development of resistant virus.
• For women for whom combination antiretroviral therapy
would be considered optional (HIV-1 RNA <1,000
copies/ml) and who wish to restrict their exposure to
antiretroviral drugs during pregnancy, monotherapy with
the three-part zidovudine (ZDV) prophylaxis regimen (or
in selected circumstances, dual nucleosides) should be
offered. In these circumstances, the development of resis-
tance should be minimized by limited viral replication
(assuming HIV-1 RNA levels remain low) and the time-
limited exposure to ZDV. Monotherapy with ZDV does
not suppress HIV-1 replication to undetectable levels in
most cases; theoretically, such therapy might select for
ZDV-resistant viral variants, potentially limiting future
treatment options. These considerations should be
discussed with the pregnant woman.
• Recommendations for resistance testing for HIV-1–
infected pregnant women are the same as for nonpreg-
nant patients: acute HIV-1 infection, virologic failure, sub-
optimal viral suppression after initiation of antiretroviral
therapy, or high likelihood of exposure to resistant virus
based on community prevalence or source characteristics.
• Women who have a history of presumed or documented
ZDV resistance and are receiving antiretroviral regimens
that do not include ZDV for their own health should still
receive intravenous ZDV intrapartum and oral ZDV
for their infants according to the PACTG 076 proto-
col whenever possible. A key mechanism by which
ZDV reduces perinatal transmission is likely through
pre- and postexposure prophylaxis of the infant, which
may be less dependent on drug sensitivity than is
reduction of viral replication. However, these women
are not good candidates for ZDV alone.
• Optimal antiretroviral prophylaxis of the infant born
to a woman with HIV-1 known to be resistant to ZDV
or other agents should be determined in consultation
with pediatric infectious disease specialists, taking
into account resistance patterns, available drug
formulations, and infant pharmacokinetic data, when
available.
• If women receiving combination therapy require tem-
porary discontinuation for any reason during preg-
nancy, all drugs should be stopped and reintroduced
simultaneously to reduce the potential for emergence
of resistance.
• Optimal adherence to antiretroviral medications is a
key part of the strategy to reduce the development of
resistance.
• Because the prevalence of drug-resistant virus is
an evolving phenomenon, surveillance is needed to
monitor the prevalence of drug-resistant virus in preg-
nant women over time and the risk of transmission of
resistant viral strains.
BOX 2. Recommendations related to antiretroviral drug resistance and drug resistance testing for pregnant women with
human immunodeficiency virus type 1 (HIV-1) infection
TABLE 4. Rate of perinatal HIV-1 transmission according to receipt of zidovudine




Study design Therapy section (%) modes (%) ratio (95% CI*)
Observational data† No ZDV 58/559 (10.4) 1,021/5,385 (19) 0.49 (0.4 –0.7)
ZDV 4/196 (2) 92/1,255 (7.3) 0.26 (0.07–0.7)
Randomized trial§ No ZDV 2/51 (4) 16/82 (20) 0.20 (0 –0.8)
ZDV 1/119 (1) 5/117 ( 4) 0.20 (0 –1.7)
* Confidence interval.
†
Source: The International Perinatal HIV Group. The mode of delivery and risk of vertical
transmission of human immunodeficiency virus type 1. A meta-analysis of 15 prospective
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The studies described previously report data
from women not receiving combination
antiretroviral therapy or undergoing routine
viral load testing, and they do not differenti-
ate in utero from intrapartum transmission.
Whether cesarean delivery offers any benefit
to the infants of women receiving highly ac-
tive combination antiretroviral regimens who
have low or undetectable maternal HIV-1 RNA
levels is unknown. Studies evaluating vertical
transmission rates according to maternal HIV-1
RNA copy number have used a variety of
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assays with different lower limits of detection, and transmis-
sion has been reported even when maternal HIV-1 RNA lev-
els were below assay quantification (52,75,143,144). There
does not appear to be a threshold of HIV-1 RNA levels below
which lack of transmission can be assured. Nevertheless, on
the basis of the upper limits of the 95% confidence interval
reported for transmission from women who have undetect-
able viral load in late pregnancy, the highest rates of transmis-
sion among such women are similar to the observed rates of
vertical transmission among women who receive ZDV and
undergo elective cesarean delivery. Transmission occurred only
once in four studies involving 29, 32, 107, and 198 women
with undetectable viral load (<500 copies/mL ) late in preg-
nancy, 95% of whom were receiving at least ZDV and almost
half receiving two or more antiretroviral agents
(78,79,145,146). Scheduled cesarean delivery is unlikely to
further reduce this low transmission rate among treated women
with undetectable viral loads, nor would it prevent in utero
transmission. Given the variability in quantification of HIV-1
RNA levels at low copy numbers, the variety of lower limits of
quantification of the tests, and the similarly low levels of peri-
natal transmission of HIV-1 at levels <1,000 copies/mL,
ACOG has chosen 1,000 copies/mL as the threshold above
which to recommend scheduled cesarean delivery as an
adjunct for prevention of transmission (142).
Similarly low vertical transmission rates have been observed
among limited numbers of women receiving combination
antiretroviral therapy during pregnancy. Three limited stud-
ies have shown transmission among one (6.7%) of 15 and
none of 30 and 24 women receiving two or more antiretroviral
drugs in combination during pregnancy (21,88,133). Addi-
tional studies in abstract form reported no transmission among
153 women receiving highly active combination antiretroviral
therapy, whereas others have reported transmission rates of
1% (2/187) and 5.8% (3/52) among women receiving triple
therapy including a protease inhibitor (147–149). Whether
the low transmission rates with combination therapy are due
to reduction in HIV-1 RNA to very low or undetectable levels
or to some other mechanism (e.g., transplacental drug pas-
sage providing preexposure prophylaxis to the infant) is
unknown because HIV-1 RNA levels were not reported. Thus,
current data are insufficient to adequately assess whether the
impact of combination antiretroviral therapy on vertical trans-
mission is independent from its effect on viral load. There-
fore, scheduled cesarean delivery is recommended for women
with HIV-1 RNA >1,000 copies/mL near the time delivery,
regardless of the type of antiretroviral therapy the woman is
receiving.
Maternal Risks by Mode of Delivery
Among women not infected with HIV-1, maternal mor-
bidity and mortality are greater after cesarean than after vagi-
nal delivery. Complications, especially postpartum infections,
are approximately five to seven times more common after
cesarean section performed after labor or membrane rupture
compared with vaginal delivery (150,151). Complications
after scheduled cesarean delivery are more common than with
vaginal delivery but less than with urgent cesarean delivery
(152–156). Factors that increase the risk of postoperative com-
plications include low socioeconomic status, genital
infections, obesity or malnutrition, smoking, and prolonged
labor or membrane rupture.
In the European mode of delivery randomized trial among
HIV-1–infected pregnant women, no major complications
occurred in either the cesarean or vaginal delivery group (141).
However, postpartum fever occurred in two (1.1%) of 183
women who delivered vaginally and 15 (6.7%) of 225 who
delivered by cesarean section (p = 0.002). Substantial post-
partum bleeding and anemia occurred at similar rates in the
two groups. Among the 497 women enrolled in PACTG 185,
only endometritis, wound infection, and pneumonia were
increased among women delivered by scheduled or urgent
cesarean section, compared with vaginal delivery (157). Com-
plication rates were within the range previously reported for
similar general obstetric populations. Finally, an analysis of
nearly 1,200 women enrolled in WITS demonstrated increased
rate of postpartum fever without documented source of infec-
tion among women undergoing elective cesarean delivery com-
pared with spontaneous vaginal delivery, but hemorrhage,
severe anemia, endometritis or urinary tract infections were
not increased (158). In the latter two studies, cesarean deliver-
ies before onset of labor and ruptured membranes were done
for obstetric indications such as previous cesarean section or
severe preeclampsia and not for prevention of HIV-1 trans-
mission, possibly resulting in higher complication rates than
might be observed for scheduled cesarean section performed
solely to reduce perinatal transmission.
In a more recent study including a cohort of HIV-1–
infected women with a larger proportion of women under-
going scheduled cesarean delivery specifically for prevention
of HIV-1 transmission, fever was increased after cesarean com-
pared with vaginal delivery (159). In a multivariate analysis
adjusted for maternal CD4+ count and antepartum hemor-
rhage, the relative risk of any postpartum complication was
1.85 (95% CI = 1.00–3.39) after elective cesarean delivery
and 4.17 (95% CI = 2.32–7.49) after emergency cesarean
delivery, compared with that for women delivering vaginally.
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Febrile morbidity was increased among women with low CD4+
counts, which was consistent with findings in previous stud-
ies (160,161).
Several case-control studies and a cohort study have reported
complication rates among HIV-1–infected versus uninfected
women undergoing cesarean delivery, usually on an urgent
rather than scheduled basis (160–166). All but one study
detected an increase in postpartum fever or antibiotic
use among the HIV-1–infected women, although increases in
specific infections such as endometritis, wound infection, or
pneumonia were found in some but not all studies. Compli-
cation rates were inversely related to CD4+ count or clinical
stage of HIV-1 disease. In the one study in which it was evalu-
ated, antiretroviral therapy with ZDV was associated with a
decreased rate of infectious complications, although this was
not statistically significant (odds ratio = 3.1, 95% CI = 0.07–
1.3) (165).
In summary, data indicate that cesarean delivery is associ-
ated with a slightly greater risk of complications among HIV-
1–infected women than observed among uninfected women,
with the difference most notable among women with more
advanced disease. Scheduled cesarean delivery for prevention
of HIV-1 transmission poses a risk greater than that of vaginal
delivery and less than that of urgent or emergent cesarean sec-
tion. Complication rates in most studies were within the range
reported in populations of HIV-1–uninfected women with
similar risk factors and were not of sufficient frequency or
severity to outweigh the potential benefit of reduced trans-
mission among women at heightened risk of transmission.
HIV-1–infected women should be counseled regarding the
increased risks associated with cesarean delivery as well as the
potential benefits based on their HIV-1 RNA levels and
current antiretroviral therapy.
Timing of Scheduled Cesarean Delivery
If the decision is made to perform a scheduled cesarean
delivery to prevent HIV-1 transmission, ACOG recommends
that it be done at 38 weeks’ gestation, determined by using
clinical and first or second trimester ultrasonographic esti-
mates of gestational age and avoiding amniocentesis (142).
For HIV-1–uninfected women, ACOG guidelines for sched-
uled cesarean delivery without confirmation of fetal lung
maturity advise waiting until 39 completed weeks or the
onset of labor to reduce the chance of complications in the
neonate (167). Cesarean delivery at 38 versus 39 weeks entails
a small absolute but substantially increased risk of develop-
ment of infant respiratory distress requiring mechanical ven-
tilation (168,169). This increased risk must be balanced against
the potential risk for labor or membrane rupture before the
woman would reach 39 weeks of gestation. Women should be
informed of the potential risks and benefits to themselves and
their infants in choosing the timing and mode of delivery.
Intrapartum Management
For a scheduled cesarean delivery, intravenous ZDV should
begin 3 hours before surgery, according to standard dosing
recommendations (2). Other antiretroviral medications taken
during pregnancy should not be interrupted near the time of
delivery, regardless of route of delivery. Because maternal
infectious morbidity is potentially increased, clinicians may
opt to give perioperative antimicrobial prophylaxis. No con-
trolled studies have evaluated the efficacy of antimicrobial pro-
phylaxis specifically for HIV-1–infected women undergoing
scheduled operative delivery (170).
Unanswered questions remain regarding the most appro-
priate management of labor in cases in which vaginal delivery
is attempted. Increasing duration of membrane rupture has
been demonstrated consistently to be a risk factor for perina-
tal transmission among women not receiving any antiretroviral
therapy (93,143,171,172). Among women receiving ZDV,
some studies have shown an increased risk of transmission
with ruptured membranes for 4 or more hours before delivery
(9,79), but others have not (78,145). The additive risk and
the critical time of ruptured membranes for perinatal HIV-1
transmission in women with low viral loads and/or receiving
combination antiretroviral therapy are unknown. Obstetric
procedures increasing the risk of fetal exposure to maternal
blood, such as amniocentesis and invasive monitoring, have
been implicated in increasing vertical transmission rates by
some but not all investigators (78,173–175). If labor is pro-
gressing and membranes are intact, artificial rupture of mem-
branes or invasive monitoring should be avoided. These
procedures should be considered only when obstetrically
indicated and the length of time for ruptured membranes or
monitoring is anticipated to be short. If spontaneous rupture
of membranes occurs before or early during the course of
labor, interventions to decrease the interval to delivery, such
as administration of pitocin, might be considered.
Summary
Considerations related to counseling of the HIV-1–infected
pregnant woman regarding risks for vertical transmission of
HIV-1 to the fetus/neonate and to the obstetric care of such
women include the following:
• Efforts to maximize the health of the pregnant woman,
including the provision of highly active combination
antiretroviral therapy, can be expected to correlate
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with both reduction in viral load and low rates of vertical
transmission. At a minimum for the reduction of perina-
tal HIV-1 transmission, ZDV prophylaxis according to
the PACTG 076 regimen is recommended unless the
woman is intolerant of ZDV.
• Plasma HIV-1 RNA levels should be monitored during
pregnancy according to the guidelines for management
of HIV-1–infected adults. The most recently determined
viral load value should be used when counseling a woman
regarding mode of delivery.
• Perinatal HIV-1 transmission is reduced by scheduled
cesarean section among women with unknown HIV-1
RNA levels who are not receiving antiretroviral therapy
or receiving ZDV for prophylaxis of perinatal transmis-
sion. Plasma HIV-1 RNA levels were not available in these
studies to assess the potential benefit among women with
low plasma HIV-1 RNA levels.
• Women with HIV-1 RNA levels >1,000 copies/mL should
be counseled regarding the benefit of scheduled cesarean
delivery in reducing the risk of vertical transmission.
• Data are insufficient to evaluate the potential benefit of
cesarean section for neonates of antiretroviral-treated
women with plasma HIV-1 RNA levels below 1,000
copies/mL. Given the low rate of transmission among this
group, it is unlikely that scheduled cesarean section would
confer additional benefit in reduction of transmission.
• Management of women originally scheduled for cesarean
delivery who present with ruptured membranes must be
individualized based on duration of rupture, progress of
labor, plasma HIV-1 RNA level, current antiretroviral
therapy, and other clinical factors.
• Women should be informed of the risks associated with
cesarean delivery, and these risks to the woman should be
balanced with potential benefits expected for the neonate.
• Women should be counseled regarding the limitations of
the current data. The woman’s autonomy to make an
informed decision regarding route of delivery should be
respected and honored.
Clinical Situations
The following recommendations are based on various
hypothetical situations that may be encountered in clinical
practice (Box 3), with relevant considerations highlighted in
the subsequent discussion sections. These recommendations
are only guidelines, and flexibility should be exercised accord-
ing to the patient’s individual circumstances.
1. HIV-1–infected women presenting in late
pregnancy (after approximately 36 weeks
of gestation), known to be HIV-1 infected but
not receiving antiretroviral therapy, and
whose results for HIV-1 RNA level and
lymphocyte subsets are pending but unlikely
to be available before delivery.
Recommendation. Therapy options should be discussed
in detail. Antiretroviral therapy, including at least the PACTG
076 ZDV regimen, should be initiated. In counseling, the
woman should be informed that scheduled cesarean section is
likely to reduce the risk of transmission to her infant. She
should also be informed of the increased risks to her of cesar-
ean delivery, including increased rates of postoperative infec-
tion, anesthesia risks, and other surgical risks. If cesarean
delivery is chosen, the procedure should be scheduled at 38
weeks of gestation, based on the best available clinical infor-
mation. When scheduled cesarean section is performed, the
woman should receive continuous intravenous ZDV infusion
beginning 3 hours before surgery, and her infant should
receive 6 weeks of ZDV therapy after birth. Options for con-
tinuing or initiating combination antiretroviral therapy after
delivery should be discussed with the woman as soon as her
viral load and lymphocyte subset results are available.
Discussion. Women in these circumstances are similar to
women enrolled in the European randomized trial and those
evaluated in the meta-analysis (140,141). In both studies, the
population not receiving antiretroviral therapy was shown to
have a significant reduction in transmission with cesarean sec-
tion done before labor or membrane rupture. HIV-1 RNA
levels were not available in these studies. Without current
therapy, the HIV-1 RNA level are unlikely to be <1,000
copies/mL. Even if combination therapy were begun immedi-
ately, reduction in plasma HIV-1 RNA to undetectable levels
usually takes several weeks, depending on the starting RNA
level. ZDV monotherapy could be begun, with subsequent
antiretroviral therapy decisions made after delivery based on
the HIV-1 RNA level, CD4+ count, and the woman’s prefer-
ence regarding initiation of long-term combination therapy.
Scheduled cesarean section and the three-part PACTG 076
ZDV regimen offer the best chance of preventing perinatal
HIV-1 transmission in this setting.
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1. HIV-1–infected women presenting in late pregnancy
(after approximately 36 weeks of gestation), known
to be HIV-1 infected but not receiving antiretroviral
therapy, and whose results for HIV RNA level and
lymphocyte subsets are pending but unlikely to be
available before delivery
• Therapy options should be discussed in detail.
Antiretroviral therapy, including at least the PACTG
076 zidovudine (ZDV) regimen, should be initiated.
In counseling, the woman should be informed that
scheduled cesarean section is likely to reduce the risk
of transmission to her infant. She should also be
informed of the increased risks to her of cesarean de-
livery, including increased rates of postoperative in-
fection, anesthesia risks, and other surgical risks.
• If cesarean delivery is chosen, the procedure should
be scheduled at 38 weeks of gestation, based on the
best available clinical information. When scheduled
cesarean section is performed, the woman should
receive continuous intravenous ZDV infusion begin-
ning 3 hours before surgery, and her infant should
receive 6 weeks of ZDV therapy after birth. Options
for continuing or initiating combination antiretroviral
therapy after delivery should be discussed with the
woman as soon as her viral load and lymphocyte
subset results are available.
2. HIV-1–infected women who began prenatal care
early in the third trimester, are receiving highly ac-
tive combination antiretroviral therapy, and have an
initial virologic response but have HIV-1 RNA lev-
els that remain substantially over 1,000 copies/mL
at 36 weeks of gestation
• The current combination antiretroviral regimen
should be continued since the HIV-1 RNA level is
dropping appropriately. The woman should be
informed that although her HIV-1 RNA level is
responding to the antiretroviral therapy, it is not likely
to decline to <1,000 copies/mL before delivery. There-
fore, scheduled cesarean section may provide addi-
tional benefit in preventing intrapartum transmission
of HIV-1. She should also be informed of the increased
risks to her of cesarean delivery, including increased
rates of postoperative infection, anesthesia risks, and
surgical risks.
• If she chooses scheduled cesarean delivery, it should
be performed at 38 weeks’ gestation, and intrave-
nous ZDV should be begun at least 3 hours before
surgery. Other antiretroviral medications should be
continued on schedule as much as possible before
and after surgery. The infant should receive oral ZDV
for 6 weeks after birth. The importance of adhering
to therapy after delivery for her own health should
be emphasized.
3. HIV-1–infected women receiving highly active com-
bination antiretroviral therapy who have an unde-
tectable HIV-1 RNA level at 36 weeks of gestation
• The woman should be informed that her risk of peri-
natal transmission of HIV-1 with a persistently
undetectable HIV-1 RNA level is low, probably 2%
or less, even with vaginal delivery. No information
is currently available on which to determine whether
performing a scheduled cesarean section will lower
her risk further.
• Cesarean delivery has an increased risk of complica-
tions for the woman compared with vaginal deliv-
ery, and these risks must be balanced against the
uncertain benefit of cesarean delivery in this case.
4. HIV-1–infected women who have elected scheduled
cesarean delivery but present in early labor or shortly
after rupture of membranes
• Intravenous ZDV should be started immediately
because the woman is in labor or has ruptured
membranes.
• If labor is progressing rapidly, the woman should be
allowed to deliver vaginally. If cervical dilatation is
minimal and a long period of labor is anticipated,
some clinicians may administer the loading dose of
intravenous ZDV and proceed with cesarean sec-
tion to minimize the duration of membrane rup-
ture and avoid vaginal delivery. Alternatively, the
clinicians might begin pitocin augmentation to
enhance contractions and potentially expedite
delivery.
• If the woman is allowed to labor, scalp electrodes
and other invasive monitoring and operative
delivery should be avoided if possible. The infant
should be treated with 6 weeks of ZDV therapy
after birth.
BOX 3. Clinical situations and recommendations regarding mode of delivery to reduce perinatal human immuno-
deficiency virus type 1 (HIV-1) transmission
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2. HIV-1–infected women who began prenatal
care early in the third trimester, are receiving
highly active combination antiretroviral
therapy, and have an initial virologic
response but have HIV-1 RNA levels that
remain substantially over 1,000 copies/mL
at 36 weeks of gestation.
Recommendation. The current combination antiretroviral
regimen should be continued because the HIV-1 RNA level is
declining appropriately. The woman should be informed that
although her HIV-1 RNA level is responding to the
antiretroviral therapy, it is unlikely that it will reach <1,000
copies/mL before delivery. Therefore, scheduled cesarean
delivery may provide additional benefit in preventing intra-
partum transmission of HIV-1. She should also be informed
of the increased risks to her of cesarean delivery, including
increased rates of postoperative infection, anesthesia risks, and
surgical risks. If she chooses scheduled cesarean section, it
should be performed at 38 weeks’ gestation, and intravenous
ZDV should be begun at least 3 hours before surgery. Other
antiretroviral medications should be continued on schedule
as much as possible before and after surgery. The infant should
receive oral ZDV for 6 weeks after birth. The importance of
adhering to therapy after delivery for her own health should
be emphasized.
Discussion. In cohorts of women receiving ZDV therapy
with low rates of scheduled cesarean delivery, current data
indicate that the rate of vertical transmission of HIV-1 is 1%–
12% (mean 5.7%) when HIV-1 RNA levels near delivery are
1,000–10,000 copies/mL, and is 9%–29% (mean 12.6%)
when HIV-1 RNA levels are >10,000 copies/mL
(52,62,74,78,79,145). Although current combination
antiretroviral therapy regimens may be expected to suppress
HIV-1 RNA to undetectable levels with continued use, these
levels are likely to still be detectable within the period of
expected delivery. Scheduled cesarean delivery might further
reduce the rate of intrapartum HIV-1 transmission and should
be recommended to women with HIV-1 RNA levels >1,000
copies/mL. Although several studies have suggested low levels
of vertical transmission of HIV-1 among pregnant women
receiving combination antiretroviral therapy, each has included
limited numbers of women and has not adjusted for maternal
HIV-1 RNA levels (61,88,133,148). Thus, it is not clear if
the impact on transmission is related to the lowering of
maternal plasma HIV-1 RNA levels, preexposure prophylaxis
of the infant, other mechanisms, or some combination. Until
further data are available, women with HIV-1 RNA levels
>1,000 copies/mL should be offered scheduled cesarean
delivery regardless of maternal therapy.
Regardless of mode of delivery, the woman should receive
the PACTG 076 intravenous ZDV regimen intrapartum, and
the infant should receive ZDV for 6 weeks after birth. Other
maternal drugs should be continued on schedule as much as
possible to provide maximal effect and minimize the chance
of development of viral resistance. Oral medications may be
continued preoperatively with sips of water. Medications
requiring food ingestion for absorption could be taken with
liquid dietary supplements, but consultation with the attend-
ing anesthesiologist should be obtained before administering
in the preoperative period. If maternal antiretroviral therapy
must be interrupted temporarily in the peripartum period, all
drugs (except for intrapartum intravenous ZDV) should be
stopped and reinstituted simultaneously to minimize the
chance of resistance developing.
Women with CD4+ counts <350 cells/mL or HIV-1 RNA
levels >55,000 copies/mL before initiation of combination
therapy during pregnancy are most likely to benefit from con-
tinued antiretroviral therapy after delivery (14). Discussion
regarding plans for antiretroviral therapy after delivery should
be initiated during pregnancy. If the woman elects to con-
tinue therapy after delivery, the importance of continued
adherence despite the increased responsibilities of newborn
care should be emphasized and any support available for the
woman should be provided.
3. HIV-1–infected women receiving highly
active combination antiretroviral therapy
who have an undetectable HIV-1 RNA level
at 36 weeks of gestation.
Recommendation. The woman should be informed that
her risk of perinatal transmission of HIV-1 with a persistently
undetectable HIV-1 RNA level is low, probably 2% or less,
even with vaginal delivery. No information is currently avail-
able on which to determine whether performing a scheduled
cesarean delivery will lower her risk further. Cesarean delivery
has an increased risk of complications for the woman com-
pared with vaginal delivery, and these risks must be balanced
against the uncertain benefit of cesarean delivery in this case.
Discussion. Scheduled cesarean delivery has been benefi-
cial for women either receiving no antiretroviral therapy or
receiving ZDV monotherapy, with rates of transmission of
HIV-1 of approximately 1%–2% (140,141). Maternal HIV-1
RNA levels were not evaluated in these studies. Similar rates
of transmission have been reported among women receiving
antiretroviral therapy, with HIV-1 RNA levels undetectable
near delivery (78,79,146). No data are available evaluating
transmission rates by mode of delivery among women with
undetectable HIV-1 RNA levels. Although a benefit of cesar-
ean delivery in reducing transmission may be present, it would
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be of small magnitude given the low risk of transmission with
vaginal delivery among women with HIV-1 RNA levels <1,000
copies/mL who are receiving maternal antiretroviral therapy.
Any benefit must be weighed against the known increased risks
to the woman with cesarean section compared with vaginal
delivery, i.e., a severalfold increased risk of postpartum infec-
tions, including uterine infections and pneumonia, anesthe-
sia risks, and surgical complications. However, given no data
to indicate lack of benefit, if a woman chooses a scheduled
cesarean delivery, her decision should be respected and cesar-
ean delivery scheduled.
If vaginal delivery is chosen, the duration of ruptured mem-
branes should be minimized because the transmission rate has
been shown to increase with longer duration of membrane
rupture among predominantly untreated women (143,171,172)
and among ZDV-treated women in some (9,79) but not all
studies (78,145). Fetal scalp electrodes and operative delivery
with forceps or the vacuum extractor may increase the risk of
transmission and should be avoided (173, 174). Intravenous
ZDV should be given during labor, and maternal drugs should
be continued on schedule as much as possible to provide maxi-
mal effect and minimize the chance of development of viral
resistance, and the infant should be treated with ZDV for 6
weeks after birth.
4. HIV-1–Infected women who have elected
scheduled cesarean section but present in
early labor or shortly after rupture of
membranes.
Recommendation. Intravenous ZDV should be started
immediately since the woman is in labor or has ruptured mem-
branes. If labor is progressing rapidly, the woman should be
allowed to deliver vaginally. If cervical dilatation is minimal
and a long period of labor is anticipated, the clinician may
administer the loading dose of intravenous ZDV and proceed
with cesarean section to minimize the duration of membrane
rupture and avoid vaginal delivery. Alternatively, the clinician
might begin pitocin augmentation to enhance contractions
and potentially expedite delivery. If the woman is allowed to
labor, scalp electrodes and other invasive monitoring and
operative delivery should be avoided if possible. The infant
should be treated with 6 weeks of ZDV therapy after birth.
Discussion. No data are available to address the question
of whether performing cesarean section soon after membrane
rupture to shorten labor and avoid vaginal delivery decreases
the risk of vertical transmission of HIV-1. Most studies have
shown the risk of transmission with cesarean section done
after labor and membrane rupture for obstetric indications to
be similar to that with vaginal delivery, although the duration
of ruptured membranes in these women was often longer than
4 hours (141,176). When an effect was demonstrated, the risk
of transmission was twice as high among women with rup-
tured membranes for >4 hours before delivery compared with
those with shorter duration of membrane rupture, although
the risk increased continuously with increasing duration of
rupture (See Situation 3).
If elective cesarean delivery had been planned and the woman
presents with a short duration of ruptured membranes or
labor, she should be informed that the benefit of cesarean
section under these circumstances is unclear and be allowed
to reassess her decision. If the woman presents after 4 hours of
membrane rupture, cesarean section is less likely to affect trans-
mission of HIV-1. The woman should be informed that the
benefit of cesarean section is unclear and that her risks of
perioperative infection increase with increasing duration of
ruptured membranes.
If cesarean delivery is chosen, the loading dose of ZDV
should be administered while preparations are made for
cesarean delivery and the infusion continued until cord clamp-
ing. Prophylactic antibiotics given after cord clamping have
been shown to reduce the rate of postpartum infection among
women of unknown HIV-1 status undergoing cesarean sec-
tion after labor or rupture or membranes and should be used
routinely in this setting (170). If vaginal delivery is chosen,
intravenous ZDV and other antiretroviral agents the woman
is currently taking should be administered and invasive pro-
cedures such as internal monitoring avoided. Pitocin should
be used as needed to expedite delivery.
Recommendations for Monitoring
of Women and Their Infants
Pregnant Woman and Fetus
HIV-1 infected pregnant women should be monitored
according to the same standards for monitoring HIV-1–
infected persons who are not pregnant. This monitoring should
include measurement of CD4+ counts and HIV-1 RNA levels
approximately every trimester (i.e., every 3 to 4 months) to
determine the need for antiretroviral therapy for maternal HIV-1
disease, whether such therapy should be altered, and whether
prophylaxis against Pneumocystis carinii pneumonia should be
initiated.
Changes in absolute CD4+ count during pregnancy may
reflect the physiologic changes of pregnancy on hemodynamic
parameters and blood volume as opposed to a long-term
influence of pregnancy on CD4+ count; CD4+ percentage is
likely more stable and might be a more accurate reflection of
immune status during pregnancy (177,178). Long-range plans
should be developed with the woman regarding continuity of
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medical care and antiretroviral therapy for her own health
after the birth of her infant.
Monitoring for potential complications of administration
of antiretroviral agents during pregnancy should be based on
what is known about the side effects of the drugs the woman
is receiving. For example, routine hematologic and liver
enzyme monitoring is recommended for women receiving
ZDV, and women receiving protease inhibitors should be
monitored for the development of hyperglycemia. Because
combination antiretroviral regimens have been used less
extensively during pregnancy, more intensive monitoring may
be warranted for women receiving drugs other than or in
addition to ZDV.
Antepartum fetal monitoring for women who receive only
ZDV chemoprophylaxis should be performed as clinically
indicated because data do not indicate that ZDV use in preg-
nancy is associated with increased risk for fetal complications.
Less is known about the effect of combination antiretroviral
therapy on the fetus during pregnancy. Thus, more intensive
fetal monitoring should be considered for mothers receiving
such therapy, including assessment of fetal anatomy with a
level II ultrasound and continued assessment of fetal growth
and wellbeing during the third trimester.
Neonate
A complete blood count and differential should be per-
formed on the newborn as a baseline evaluation before
administration of ZDV. Anemia has been the primary com-
plication of the 6-week ZDV regimen in the neonate; thus,
repeat measurement of hemoglobin is required at a minimum
after the completion of the 6-week ZDV regimen. If abnor-
mal, repeat measurement should be performed at age 12 weeks,
by which time any ZDV-related hematologic toxicity should
be resolved. Infants who have anemia at birth or who are born
prematurely warrant more intensive monitoring.
Data are limited concerning potential toxicities in infants
whose mothers have received combination antiretroviral
therapy. More intensive monitoring of hematologic and
serum chemistry measurements during the first few weeks of
life is advised for these infants. However, it should be noted
that the clinical relevance of lactate levels in the neonatal
period to assess potential for mitochondrial toxicity has not
been adequately evaluated.
To prevent P. carinii pneumonia, all infants born to women
with HIV-1 infection should begin prophylaxis at age 6 weeks,
after completion of the ZDV prophylaxis regimen (179).
Monitoring and diagnostic evaluation of HIV-1–exposed
infants should follow current standards of care (180). Data do
not indicate any delay in HIV-1 diagnosis in infants who have
received the ZDV regimen (1,181). However, the effect of
combination antiretroviral therapy in the mother or newborn
on the sensitivity of infant virologic diagnostic testing is
unknown. Infants with negative virologic test results during
the first 6 weeks of life should have diagnostic evaluation
repeated after completion of the neonatal antiretroviral
prophylaxis regimen.
Postpartum Follow-Up of Women
Comprehensive care and support services are important for
women with HIV-1 infection and their families. Components
of comprehensive care include the following medical and
supportive care services:
• Primary, obstetric, pediatric, and HIV-1 specialty care,
• Family planning services,
• Mental health services,
• Substance-abuse treatment, and
• Coordination of care through case management for the
woman, her children, and other family members.
Support services include case management, child care,
respite care, assistance with basic life needs (e.g., housing, food,
and transportation), and legal and advocacy services. This care
should begin before pregnancy and should be continued
throughout pregnancy and postpartum.
Maternal medical services during the postpartum period
must be coordinated between obstetric care providers and HIV-1
specialists. Continuity of antiretroviral treatment when such
treatment is required for the woman’s HIV-1 infection is
especially critical and must be ensured. Concerns have been
raised about adherence to antiretroviral regimens during the
postpartum period. Women should be counseled about the
fact that the physical changes of the postpartum period, as
well as the stresses and demands of caring for a new baby, can
make adherence more difficult and additional support may
be needed to maintain good adherence to their therapeutic
antiretroviral regimen during this period (182,183). The
health-care provider should be vigilant for signs of depres-
sion, which may require assessment and treatment and which
may interfere with adherence. Poor adherence has been shown
to be associated with virologic failure, development of resis-
tance, and decreased long-term effectiveness of antiretroviral
therapy (184–189). Efforts to maintain good adherence dur-
ing the postpartum period might prolong the effectiveness of
therapy (14).
All women should receive comprehensive health-care ser-
vices that continue after pregnancy for their own medical care
and for assistance with family planning and contraception. In
addition, this is a good time to review immunization status
and update vaccines, assess the need for prophylaxis against
opportunistic infections, and reemphasize safer sex practices.
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Data from PACTG 076 and 288 do not indicate adverse
effects through 4 years postpartum among women who
received ZDV during pregnancy (47, 132). Women who have
received only ZDV chemoprophylaxis during pregnancy
should receive appropriate evaluation to determine the need
for antiretroviral therapy during the postpartum period.
Long-Term Follow-Up of Infants
Data remain insufficient to address the effect that exposure
to ZDV or other antiretroviral agents in utero might have on
long-term risk for neoplasia or organ system toxicities in chil-
dren. Data from follow-up of PACTG 076 infants through
age 6 years do not indicate any differences in immunologic,
neurologic, and growth parameters between infants who were
exposed to the ZDV regimen and those who received
placebo, and no malignancies have been seen (58,59). Con-
tinued evaluation of early and late effects of in utero
antiretroviral exposure is ongoing through several mechanisms,
including a long-term follow-up study in the Pediatric AIDS
Clinical Trials Group (PACTG 219C), natural history stud-
ies, and HIV/AIDS surveillance conducted by state health
departments and CDC. Because most of the available follow-
up data relate to in utero exposure to antenatal ZDV alone
and most pregnant women with HIV-1 infection currently
receive combination therapy, it is critical that studies to evalu-
ate potential adverse effects of in utero drug exposure
continue to be supported.
Innovative methods are needed to provide follow-up of
infants with in utero exposure to antiretroviral drugs. Infor-
mation regarding such exposure should be part of the
ongoing permanent medical record of the child, particularly
for uninfected children. Children with in utero antiretroviral
exposure who develop significant organ system abnormalities
of unknown etiology, particularly of the nervous system or
heart, should be evaluated for potential mitochondrial
dysfunction (46). Follow-up of children with antiretroviral
exposure should continue into adulthood because of the theo-
retical concerns regarding potential for carcinogenicity of the
nucleoside analog antiretroviral drugs. Long-term follow-up
should include yearly physical examinations of all children
exposed to antiretroviral drugs and, for adolescent females,
gynecologic evaluation with Pap smears.
HIV-1 surveillance databases from states that require HIV-1
reporting provide an opportunity to collect population-based
information concerning in utero antiretroviral exposure. To
the extent permitted by federal law and regulations, data from
these confidential registries can be used to compare with
information from birth defect and cancer registries to identify
potential adverse outcomes.
Clinical Research Needs
The following clinical research needs are relevant to the
United States and other developed countries. Study findings
continue to evolve rapidly, and research needs and clinical
practice will require continued reassessment over time. The
current guidelines do not attempt to address the complex
research needs or antiretroviral prophylaxis recommendations
for resource-limited international settings.
Evaluation of Drug Safety and
Pharmacokinetics
Many pregnant women with HIV-1 infection in the United
States are receiving combination antiretroviral therapy for their
own health care along with standard ZDV prophylaxis to
reduce perinatal HIV-1 transmission. Additionally, recent data
indicate that antenatal use of potent antiretroviral combina-
tions capable of reducing plasma HIV-1 RNA copy number
to very low or undetectable levels near the time of delivery
may lower the risk of perinatal transmission to <2% (61,90).
While the number of antiretroviral agents and combination
regimens used for treatment of infected persons is increasing
rapidly, the number of drugs evaluated in pregnant women
remains limited.
Preclinical evaluations of antiretroviral drugs for potential
pregnancy- and fetal-related toxicities need to be completed
for all existing and new antiretroviral drugs. More data are
needed regarding the safety and pharmacokinetics of
antiretroviral drugs in pregnant women and their neonates,
particularly when used in combination regimens. Further
research is also needed on whether the effects of intensive com-
bination treatment on viral load differ in various body com-
partments, such as plasma and genital tract secretions, and
how this may relate to risk of perinatal transmission.
Continued careful assessment for potential short- and long-
term consequences of antiretroviral drug use during pregnancy
for both the woman and her child is important. Consequences
of particular concern include mitochondrial dysfunction;
hepatic, hematologic and other potential end-organ toxici-
ties; development of antiretroviral drug resistance; and adverse
effects on pregnancy outcome. Because the late consequences
of in utero antiretroviral exposure for the child are unknown,
innovative methods need to be developed to detect possible
rare late toxicities of transient perinatal antiretroviral drug
exposure that may not be observed until later in childhood or
in adolescence or adulthood.
Assessment of Drug Resistance
The risk of emerging drug resistance during pregnancy
or the postpartum period requires further study. The
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administration of ZDV as a single drug for prophylaxis of
transmission may increase the incidence of ZDV resistance
mutations in women with viral replication that is not maxi-
mally suppressed. Administration of drugs such as nevirapine
and 3TC, for which a single-point mutation can confer geno-
typic resistance, to pregnant women with inadequate viral
suppression may result in the development of virus with ge-
notypic drug resistance in a substantial proportion of the
women (27,136,137). The clinical consequences of emergence
o f
genotypic resistance during pregnancy or in the postpartum
period with respect to risk of transmission of resistant virus
and future treatment options require further assessment.
Optimizing Adherence
The complexity of combination antiretroviral regimens as
well as drugs for prophylaxis against opportunistic infections
often leads to poor adherence among HIV-1–infected persons.
Innovative approaches are needed to improve adherence for
women with HIV-1 infection during and following pregnancy
and to ensure that infants receive ZDV prophylaxis.
Role of Cesarean Delivery Among Women
with Nondetectable Viral Load or with Short
Duration of Ruptured Membranes
Elective cesarean delivery has increased among women with
HIV-1 infection since the demonstration that delivery before
labor and membrane rupture can reduce intrapartum HIV-1
transmission (140,141,190). Further study is needed regard-
ing whether elective cesarean delivery provides clinically sig-
nificant benefit to infected women with low or undetectable
viral load who are receiving combination antiretroviral therapy,
and also regarding the maternal and infant morbidity and mor-
tality associated with operative delivery. Additionally, data from
a meta-analysis by the International Perinatal HIV-1 Group
indicate that the risk of perinatal transmission increases by
2% for every 1-hour increase in duration of membrane rup-
ture in infected women with <24 hours of membrane rupture
(191). Therefore, further study is also needed to evaluate
the role of nonelective cesarean delivery in reducing perinatal
transmission in women with very short duration of ruptured
membranes and/or labor.
Management of Women with Premature
Rupture of Membranes
With evidence that increasing duration of membrane rup-
ture is associated with an increasing transmission risk (191),
more study is needed to determine the appropriate manage-
ment of pregnant women with HIV-1 infection who present
with ruptured membranes at different points in gestation.
Offering Rapid Testing at Delivery to
Late-Presenting Women
One of the groups still at high risk for transmitting HIV-1
to their infants is those women who have not received antena-
tal care and were not offered HIV-1 counseling and testing.
The feasibility of offering counseling and rapid HIV-1 testing
to women of unknown HIV-1 status who present while in
labor requires further study. Additionally, the efficacy and
acceptability of intrapartum/postpartum or postpartum
infant interventions to reduce the risk of intrapartum trans-
mission by women first identified as infected with HIV-1
during delivery needs to be assessed.
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1. All of the following statements regarding perinatal HIV-1
transmission and mode of delivery are true except:
A. The recommended gestational age to perform an elective (scheduled)
cesarean delivery for prevention of mother-to-child HIV-1
transmission is 38 weeks’ gestation.
B. The risk of perinatal HIV-1 transmission has been shown to be
reduced by scheduled cesarean section before labor for women with
viral loads <1,000 copies/mL.
C. When scheduled cesarean delivery is to be performed, the intravenous
infusion of zidovudine (ZDV) prophylaxis should be initiated 3 hours
before surgery.
D. Women should make their own decisions regarding mode of delivery
after discussing the known potential risks and benefits with their
provider.
2. An initial clinical assessment of an HIV-1–infected pregnant woman
should include. . .
A. an evaluation of the degree of existing immunodeficiency determined
by CD4+ count.
B. history of prior or current antiretroviral therapy.
C. gestational age.
D. risk for disease progression as determined by the level of plasma
HIV-1 RNA.
E. supportive care needs.
F. all of the above.
3. Which of the following statements represent known complications of
antiretroviral therapy in HIV-1-infected women?
A. Combination antiretroviral therapy during pregnancy is associated with
adverse pregnancy outcome, including preterm delivery and low birth weight.
B. Hyperglycemia has been observed with protease inhibitor treatment.
C. Severe lactic acidosis in late pregnancy has been observed in HIV-1–
infected women who received d4T-ddI (stavudine-didanosine) as part
of a combination antiretroviral regimen during pregnancy.
D. B and C only.
E. All of the above.
4. The mechanism(s) by which antiretroviral prophylaxis reduces
mother-to-child- transmission is. . .
A. reducing maternal antenatal plasma HIV-1 viral load.
B. transplacental passage of antiretroviral agents to the fetus before
passage through the birth canal, providing preexposure prophylaxis of
the fetus.
C. provision of antiretroviral drugs to the infant after birth, providing
postexposure prophylaxis of the infant against virus or infected cells
that may have entered the infant’s circulation during delivery.
D. all of the above.
5. When prescribing antiretroviral therapy for a pregnant woman, a
clinician should. . .
A. aim to decrease antenatal plasma HIV-1 viral load to undetectable or
<1000 copies/ml.
B. consider the short- and long-term effects of the antiretroviral drugs on
the pregnant woman and on the fetus/infant.
C. consider potential changes in antiretroviral drug dosing requirements
caused by pregnancy.
D. discuss with the woman her ability to adhere to the considered regimen.
E. all of the above.
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perinatal HIV-1 transmission, and 4) describe the information that pregnant women should receive when making decisions about antiretroviral therapy during
pregnancy.
To receive continuing education credit, please answer all of the following questions.
6. Antiretroviral drugs that should be avoided in antiretroviral drug
regimens for HIV-1-infected pregnant women or for HIV-1-infected





E. all of the above.
F. B and C only.
7. If a woman in labor and delivery has no history of prenatal care and
has a rapid HIV-1 test or an expedited enzyme-link immunoassay
(EIA) that is positive for HIV-1 antibody, which course of
antiretroviral therapy should be administered?
A. None. Antiretroviral therapy should be administered only after
obtaining a confirmatory EIA and Western blot.
B. A single dose of nevirapine to the woman as soon as possible, followed
by a single dose of nevirapine to the newborn at age 48 hours.
C. Oral ZDV and 3TC during labor, followed by 1 week of oral ZDV-
3TC for the newborn.
D. The single-dose maternal/infant nevirapine regimen (choice B) plus
intravenous ZDV during labor and delivery and 6 weeks of ZDV for
the newborn.
E. Intravenous ZDV during labor and delivery and 6 weeks of ZDV for
the newborn.
F. Any of the above except A.
8. Why should dual nucleoside therapy not be the first choice of
treatment regimens for pregnant women infected with HIV-1?
A. Poor acceptability among pregnant women.
B. Dual nucleoside therapy has been shown increase fetal mortality.
C. Concerns exist regarding the potential for inadequate viral suppression
and rapid development of resistance.
D. Dual nucleoside therapy is ineffective in preventing perinatal HIV-1
transmission.
9. In clinical trials, single-dose nevirapine to the mother in labor and to
the infant 2 days after birth has been demonstrated to dramatically
reduce perinatal HIV-1 transmission. Given these findings, single-
dose maternal/infant nevirapine should be added to the intrapartum
regimen of women already receiving prenatal antiretroviral therapy.
A. True.
B. False.
10. If a woman has received antiretroviral therapy during pregnancy and
has undergone a scheduled elective cesarean delivery for prevention of
perinatal HIV-1 transmission, administration of ZDV to the infant for
6 weeks is not necessary.
A. True.
B. False.































































































































































































11. The recommendation for prevention of mother-to-child HIV-1
transmission in infants born to HIV-1-infected women who have not
received antiretroviral therapy during pregnancy or labor is. . .
A. ZDV, starting at age 72 hours and continued for 6 weeks.
B. single dose of ZDV at birth.
C. immediate HIV-1 DNA PCR to determine HIV-1 infection status,
with initiation of ZDV prophylaxis for 6 weeks if the test result is
negative.
D. ZDV, starting within 6–12 hours of birth and continued for 6 weeks.
12. Follow-up of HIV-1–uninfected children with in utero exposure to
antiretroviral prophylaxis. . .
A. is unnecessary once an infant is determined to be uninfected.
B. should continue through age 18 months.
C. should continue until age 5 years.
D. should continue long term to adulthood.
13. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.




D. Patient care—private medical setting.
E. Client care—publicly funded site.
F. Public health.
15. I plan to use these recommendations as the basis for. . . (Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
16. Each month, approximately how many HIV+ women of childbearing







17. How much time did you spend reading this report and completing the exam?
A. Less than 1.5 hours.
B. More than 1.5 hours but fewer than 2 hours.
C. 2–2.5  hours.
D. More than 2.5 hours but fewer than 3 hours.
E. 3 hours or more.
18. After reading this report, I am confident I can describe the
recommendations for antiretroviral therapy of HIV-1-infected women
and their infants to help reduce perinatal HIV-1 transmission in a
variety of different situations (no prior therapy; currently receiving
therapy; no antenatal therapy; no antenatal or intrapartum therapy).
A. Strongly agree.
B. Agree.
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19. After reading this report, I am confident I can identify potential
toxicities of antiretroviral drugs in pregnant women and their infants.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
20. After reading this report, I am confident I can describe when
scheduled cesarean delivery is recommended for HIV-infected
pregnant women to help reduce perinatal HIV transmission.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
21. After reading this report, I am confident I can describe the
information that should be provided to pregnant HIV-infected
women to assist them in making decisions about choice of
antiretroviral therapy during pregnancy.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
22. Overall, the objectives are relevant to the goal of this report.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree or disagree.
23. The tables and text boxes are useful.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
25. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
26. The availability of continuing education credit influenced my decision
to read this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
27. How did you learn about this continuing education activity?
A. Internet





Correct answers for questions 1–12.
1. B; 2. F; 3. D; 4. D; 5. E; 6. F; 7. F; 8. C; 9. B; 10. B; 11. D; 12. D
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